<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Nat Rev Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Nat Rev Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">3814</journal-id><journal-id journal-id-type="pmc-domain">phenaturepg</journal-id><journal-title-group><journal-title>Nature Reviews. Immunology</journal-title></journal-title-group><issn pub-type="ppub">1474-1733</issn><issn pub-type="epub">1474-1741</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer Nature - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9812358</article-id><article-id pub-id-type="pmcid-ver">PMC9812358.1</article-id><article-id pub-id-type="pmcaid">9812358</article-id><article-id pub-id-type="pmcaiid">9812358</article-id><article-id pub-id-type="pmid">36600071</article-id><article-id pub-id-type="doi">10.1038/s41577-022-00826-w</article-id><article-id pub-id-type="publisher-id">826</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Immune responses to human fungal pathogens and&#160;therapeutic prospects</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-4994-9500</contrib-id><name name-style="western"><surname>Lionakis</surname><given-names initials="MS">Michail S.</given-names></name><address><email>lionakism@mail.nih.gov</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5424-7074</contrib-id><name name-style="western"><surname>Drummond</surname><given-names initials="RA">Rebecca A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9097-5412</contrib-id><name name-style="western"><surname>Hohl</surname><given-names initials="TM">Tobias M.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.94365.3d</institution-id><institution-id institution-id-type="ISNI">0000 0001 2297 5165</institution-id><institution>Fungal Pathogenesis Section, Laboratory of Clinical Immunology, National Institute of Allergy and Infectious Diseases, </institution><institution>National Institutes of Health, </institution></institution-wrap>Bethesda, MD USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.6572.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7486</institution-id><institution>Institute of Immunology and Immunotherapy, </institution><institution>University of Birmingham, </institution></institution-wrap>Birmingham, UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.6572.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 7486</institution-id><institution>Institute of Microbiology and Infection, </institution><institution>University of Birmingham, </institution></institution-wrap>Birmingham, UK </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Infectious Disease Service, Department of Medicine, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Immunology Program, Sloan Kettering Institute, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.51462.34</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9952</institution-id><institution>Human Oncology and Pathogenesis Program, </institution><institution>Memorial Sloan Kettering Cancer Center, </institution></institution-wrap>New York, NY USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.5386.8</institution-id><institution-id institution-id-type="ISNI">000000041936877X</institution-id><institution>Department of Medicine, </institution><institution>Weill Cornell Medical College, </institution></institution-wrap>New York, NY USA </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>1</month><year>2023</year></pub-date><issue-id pub-id-type="pmc-issue-id">425238</issue-id><fpage>1</fpage><lpage>20</lpage><history><date date-type="accepted"><day>1</day><month>12</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>05</day><month>01</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-07-24 22:25:21.887"><day>24</day><month>07</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41577_2022_Article_826.pdf"/><abstract id="Abs1"><p id="Par1">Pathogenic fungi have emerged as significant causes of infectious morbidity and death in patients with acquired immunodeficiency conditions such as HIV/AIDS and following receipt of chemotherapy, immunosuppressive agents or targeted biologics for neoplastic or autoimmune diseases, or transplants for end organ failure. Furthermore, in recent years, the spread of multidrug-resistant <italic toggle="yes">Candida auris</italic> has caused life-threatening outbreaks in health-care facilities worldwide and raised serious concerns for global public health. Rapid progress in the discovery and functional characterization of inborn errors of immunity that predispose to fungal disease and the development of clinically relevant animal models have enhanced our understanding of fungal recognition and effector pathways and adaptive immune responses. In this Review, we synthesize our current understanding of the cellular and molecular determinants of mammalian antifungal immunity, focusing on observations that show promise for informing risk stratification, prognosis, prophylaxis and therapies to combat life-threatening fungal infections in vulnerable patient populations.</p></abstract><abstract id="Abs2" abstract-type="web-summary"><p id="Par2">This Review synthesizes our current mechanistic understanding of the cellular and molecular determinants of tissue-specific antifungal host defences derived from animal models of fungal disease, humans with fungal infection-manifesting inborn errors of immunity and patients treated with fungal infection-promoting, immune-targeted biologics.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Antimicrobial responses</kwd><kwd>Fungal host response</kwd><kwd>Fungal infection</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par3">Of the approximately five million fungal species, only a few regularly infect humans. However, in recent decades, the AIDS pandemic and the increasing number of patients who have received myeloablative chemotherapy and/or solid organ or haematopoietic stem cell transplantation (HSCT) have led to a marked increase in the global burden of fungal disease in these immunocompromised individuals (Table&#160;<xref rid="Tab1" ref-type="table">1</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">1</xref>). Furthermore, new at-risk populations have emerged, including patients with severe respiratory virus-associated mould disease and individuals being treated with novel, precision immune-targeted biologics (monoclonal antibodies or small-molecule kinase inhibitors) for autoimmune, inflammatory and/or neoplastic disorders<sup><xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref></sup>. Emerging fungi such as multidrug-resistant <italic toggle="yes">Candida auris</italic> present new threats to public health<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> (Box&#160;<xref rid="Sec2" ref-type="sec">1</xref>). Fungi exhibit distinct morphotypes (such as&#160;<xref rid="Glos1" ref-type="list">yeast</xref> and <xref rid="Glos2" ref-type="list">hyphae</xref>) and can cause superficial and life-threatening invasive infections, primarily in immunocompetent individuals and immunocompromised individuals, respectively (Table&#160;<xref rid="Tab1" ref-type="table">1</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">1</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Clinical features of the most prevalent human fungal infections</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Infection (most common fungal genera or species)</th><th colspan="1" rowspan="1">Fungal morphotype</th><th colspan="1" rowspan="1">Clinical presentation</th><th colspan="1" rowspan="1">Commonly affected patient population<sup>a</sup></th><th colspan="1" rowspan="1">Annual global incidence; all-cause mortality</th><th colspan="1" rowspan="1">Current principles of treatment</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">Mucocutaneous candidiasis<sup>b</sup> (<italic toggle="yes">Candida albicans</italic>, <italic toggle="yes">Candida dubliniensis</italic>, <italic toggle="yes">Candida glabrata</italic>)</td><td rowspan="2" colspan="1">Yeast (with pseudohyphae and hyphae depending on the species)</td><td colspan="1" rowspan="1">Oropharyngeal or oesophageal candidiasis</td><td colspan="1" rowspan="1">HIV/AIDS, corticosteroid use</td><td colspan="1" rowspan="1">~3.3 million (HIV/AIDS only); NA</td><td rowspan="2" colspan="1">Topical or oral azoles; echinocandins (for azole-resistant <italic toggle="yes">Candida</italic> strains)</td></tr><tr><td colspan="1" rowspan="1">Vaginal candidiasis</td><td colspan="1" rowspan="1">Healthy women, antibiotic use</td><td colspan="1" rowspan="1">~138 million; NA</td></tr><tr><td rowspan="3" colspan="1">Invasive candidiasis (<italic toggle="yes">C. albicans</italic>, <italic toggle="yes">C. glabrata</italic>, <italic toggle="yes">Candida tropicalis</italic>, <italic toggle="yes">Candida parapsilosis</italic>, <italic toggle="yes">Candida auris</italic>)</td><td rowspan="3" colspan="1">Yeast (with pseudohyphae and hyphae depending on the species)</td><td colspan="1" rowspan="1">Candidaemia</td><td colspan="1" rowspan="1">Critical illness (ICU), after COVID-19</td><td rowspan="3" colspan="1">~750,000; ~30&#8211;40%</td><td rowspan="3" colspan="1">Echinocandins; removal of central venous catheter</td></tr><tr><td colspan="1" rowspan="1">Intra-abdominal candidiasis</td><td colspan="1" rowspan="1">Abdominal surgery</td></tr><tr><td colspan="1" rowspan="1">Disseminated candidiasis</td><td colspan="1" rowspan="1">Neutropenia, corticosteroid use, SOT, low birthweight premature neonates</td></tr><tr><td rowspan="2" colspan="1">Invasive aspergillosis (<italic toggle="yes">Aspergillus fumigatus</italic>, <italic toggle="yes">Aspergillus flavus</italic>, <italic toggle="yes">Aspergillus terreus</italic>, <italic toggle="yes">Aspergillus niger</italic>)</td><td rowspan="2" colspan="1">Filamentous mould</td><td colspan="1" rowspan="1">Pulmonary or disseminated aspergillosis</td><td colspan="1" rowspan="1">Neutropenia, corticosteroid use, HSCT, SOT, after influenza or COVID-19, ibrutinib therapy</td><td colspan="1" rowspan="1">~300,000; ~30&#8211;50%</td><td colspan="1" rowspan="1">Voriconazole (first line), isavuconazole or posaconazole; reduction of immunosuppression</td></tr><tr><td colspan="1" rowspan="1">Allergic bronchopulmonary aspergillosis</td><td colspan="1" rowspan="1">Atopic individuals</td><td colspan="1" rowspan="1">~5 million<sup>c</sup>; NA</td><td colspan="1" rowspan="1">Itraconazole and corticosteroids</td></tr><tr><td rowspan="2" colspan="1">Cryptococcosis<sup>b</sup> (<italic toggle="yes">Cryptococcus neoformans, C. gattii</italic>)</td><td rowspan="2" colspan="1">Yeast</td><td colspan="1" rowspan="1">Pneumonia</td><td colspan="1" rowspan="1">HIV/AIDS, corticosteroid use</td><td rowspan="2" colspan="1">~223,000 (HIV/AIDS only); ~20&#8211;70%</td><td rowspan="2" colspan="1">Amphotericin B (+ 5-flucytosine for CNS disease) followed by fluconazole; reduction of immunosuppression</td></tr><tr><td colspan="1" rowspan="1">CNS or disseminated cryptococcosis</td><td colspan="1" rowspan="1">HIV/AIDS, HSCT, ibrutinib therapy</td></tr><tr><td rowspan="2" colspan="1">Pneumocystosis<sup>b</sup> (<italic toggle="yes">Pneumocystis jirovecii</italic>)</td><td rowspan="2" colspan="1">Cysts and trophozoites</td><td colspan="1" rowspan="1">Pneumonia</td><td colspan="1" rowspan="1">HIV/AIDS, corticosteroid use</td><td rowspan="2" colspan="1">~500,000; ~20&#8211;80%</td><td rowspan="2" colspan="1">Trimethoprim&#8211;sulfamethoxazole; reduction of immunosuppression</td></tr><tr><td colspan="1" rowspan="1">Disseminated infection</td><td colspan="1" rowspan="1">HIV/AIDS</td></tr></tbody></table><table-wrap-foot><p>An expanded version of Table&#160;<xref rid="Tab1" ref-type="table">1</xref> is presented in Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">1</xref>. CNS, central nervous system; HSCT, haematopoietic stem cell transplantation; ICU, intensive care unit; NA, not applicable; SOT, solid organ transplantation. <sup>a</sup>At-risk conditions caused by inborn errors of immunity or administration of immune pathway-targeted biologics are presented separately in Tables&#160;<xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>. <sup>b</sup>AIDS-defining illness. <sup>c</sup>Global burden of infection.</p></table-wrap-foot></table-wrap></p><p id="Par4">Thus, interest in fungal immunology research has increased in recent years, catalysed by our growing understanding of the biology and functions of C-type lectin receptors (CLRs)<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></sup>, which are the main class of fungal-sensing pattern recognition receptors (reviewed in ref. <xref ref-type="bibr" rid="CR5">5</xref>). Notably, humans with inherited deficiency of the CLR adaptor protein CARD9 are susceptible to severe mucocutaneous and invasive fungal disease, without developing other infectious or non-infectious complications; this selective susceptibility to fungal infection is a unique feature among the more than 450 known&#160;<xref rid="Glos3" ref-type="list">inborn errors of immunity</xref> (see later)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. In this Review, we synthesize immunological insights from the expanding number of inborn errors of immunity that predispose to fungal infection (Table&#160;<xref rid="Tab2" ref-type="table">2</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>) and from fungal infection-promoting, immune-targeted biologics (Table&#160;<xref rid="Tab3" ref-type="table">3</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">3</xref>), together with mechanistic insights from animal models of fungal disease. We focus on observations that have translational implications for informing risk stratification, prognosis, treatment and vaccination of fungus-infected individuals. The text is structured according to the clinical disease phenotypes that are caused by various pathogenic yeasts, moulds and dimorphic endemic fungi.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Key human inborn errors of immunity that predispose to fungal infection</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Gene [protein name] (chromosome arm)</th><th colspan="1" rowspan="1">Predominant cellular expression</th><th colspan="1" rowspan="1">OMIM no. (clinical syndrome)</th><th colspan="1" rowspan="1">Mode of inheritance</th><th colspan="1" rowspan="1">Fungal infection susceptibility</th><th colspan="1" rowspan="1">Other clinical phenotypes</th><th colspan="1" rowspan="1">Antifungal immunological defects</th></tr></thead><tbody><tr><td colspan="1" rowspan="1"><italic toggle="yes">CARD9</italic> (9q)</td><td colspan="1" rowspan="1">Myeloid phagocytes and to a lesser extent epithelial cells</td><td colspan="1" rowspan="1">212050</td><td colspan="1" rowspan="1">AR (LOF)</td><td colspan="1" rowspan="1">CMC, CNS candidiasis, phaeohyphomycosis, aspergillosis, skin mucormycosis, onychomycosis, deep dermatophytosis</td><td colspan="1" rowspan="1">None</td><td colspan="1" rowspan="1">Decreased number of blood T<sub>H</sub>17 cells, impaired cytokine responses by PBMCs and microglia, impaired neutrophil recruitment to the CNS and killing of unopsonized <italic toggle="yes">Candida</italic> yeasts</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">STAT1</italic> (2q)</td><td colspan="1" rowspan="1">Broadly expressed</td><td colspan="1" rowspan="1">614162</td><td colspan="1" rowspan="1">AD (GOF)</td><td colspan="1" rowspan="1">Invasive candidiasis, CMC, aspergillosis, mucormycosis, PJP, cryptococcosis, histoplasmosis, coccidioidomycosis</td><td colspan="1" rowspan="1">Bacterial, NTM and viral infections, autoimmunity, aneurysms, carcinomas</td><td colspan="1" rowspan="1">Decreased number of blood T<sub>H</sub>17 cells and decreased IL-17 production by PBMCs associated with increased cellular responses to IFN&#945;/&#946;, IFN&#947; and IL-27</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">STAT3</italic> (17q)</td><td colspan="1" rowspan="1">Broadly expressed</td><td colspan="1" rowspan="1">147060 (AD HIES, Job syndrome)</td><td colspan="1" rowspan="1">AD (DN)</td><td colspan="1" rowspan="1">CMC, dermatophytosis, aspergillosis, cryptococcosis, histoplasmosis, gastrointestinal tract coccidioidomycosis, skin fusariosis, PJP</td><td colspan="1" rowspan="1">Skin staphylococcal infections, bacterial pneumonias, eczema, pneumatoceles, aneurysms, skeletal abnormalities,&#160;increased IgE</td><td colspan="1" rowspan="1">Decreased number of blood T<sub>H</sub>17&#160;cells</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">IL12RB1</italic> (19p)</td><td colspan="1" rowspan="1">Lymphoid and myeloid cells</td><td colspan="1" rowspan="1">614891 (MSMD)</td><td colspan="1" rowspan="1">AR (LOF)</td><td colspan="1" rowspan="1">CMC, cryptococcosis, histoplasmosis, coccidioidomycosis, paracoccidioidomycosis</td><td colspan="1" rowspan="1"><italic toggle="yes">Salmonella</italic> and NTM infections</td><td colspan="1" rowspan="1">Impaired T<sub>H</sub>17 cell differentiation, impaired IL-12-dependent and IL-23-dependent IFN&#947; production</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">IL17RA</italic> (22q)</td><td colspan="1" rowspan="1">Myeloid cells and epithelial cells</td><td colspan="1" rowspan="1">613953</td><td rowspan="2" colspan="1">AR (LOF)</td><td rowspan="2" colspan="1">CMC</td><td colspan="1" rowspan="1">Skin staphylococcal infections, bacterial pneumonias, eczema</td><td rowspan="2" colspan="1">Abolished IL-17 cellular responses</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">IL17RC</italic> (3p)</td><td colspan="1" rowspan="1">Epithelial cells</td><td colspan="1" rowspan="1">616445</td><td colspan="1" rowspan="1">None</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">AIRE</italic> (21q)</td><td colspan="1" rowspan="1">mTECs and eTACs</td><td colspan="1" rowspan="1">240300 (APECED)</td><td colspan="1" rowspan="1">AR (LOF) or AD (DN)</td><td colspan="1" rowspan="1">CMC</td><td colspan="1" rowspan="1">Multiorgan autoimmunity, ectodermal dystrophy, severe COVID-19</td><td colspan="1" rowspan="1">Neutralizing serum autoantibodies to IL-17A, IL-17F and IL-22, epithelial barrier disruption caused by IFN&#947; produced by mucosal T cells</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">CYBB</italic> [gp91<sup>phox</sup>] (Xp)</td><td rowspan="4" colspan="1">Myeloid phagocytes</td><td colspan="1" rowspan="1">306400 (X-linked CGD)</td><td colspan="1" rowspan="1">X-linked (LOF)</td><td rowspan="4" colspan="1">Aspergillosis, invasive candidiasis</td><td rowspan="4" colspan="1">Invasive infections with <italic toggle="yes">Nocardia</italic>, <italic toggle="yes">Staphylococcus</italic>, <italic toggle="yes">Serratia</italic> and <italic toggle="yes">Burkholderia</italic>, IBD</td><td rowspan="4" colspan="1">Impaired generation of superoxide</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">NCF2</italic> [p67<sup>phox</sup>] (1q)</td><td colspan="1" rowspan="1">233710 (AR CGD)</td><td rowspan="3" colspan="1">AR (LOF)</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">CYBA</italic> [p22<sup>phox</sup>] (16q)</td><td colspan="1" rowspan="1">233690 (AR CGD)</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">NCF1</italic> [p47<sup>phox</sup>] (7q)</td><td colspan="1" rowspan="1">233700 (AR CGD)</td></tr><tr><td rowspan="2" colspan="1"><italic toggle="yes">IFNGR1</italic> (6q)</td><td rowspan="2" colspan="1">Broadly expressed</td><td colspan="1" rowspan="1">209950 (AR MSMD)</td><td colspan="1" rowspan="1">AR (LOF)</td><td rowspan="2" colspan="1">Histoplasmosis, coccidioidomycosis</td><td rowspan="2" colspan="1"><italic toggle="yes">Salmonella</italic> and NTM infections</td><td rowspan="2" colspan="1">Impaired IFN&#947; cellular responses</td></tr><tr><td colspan="1" rowspan="1">615978 (AD MSMD)</td><td colspan="1" rowspan="1">AD (DN)</td></tr><tr><td colspan="1" rowspan="1"><italic toggle="yes">GATA2</italic> (3q)</td><td colspan="1" rowspan="1">Neutrophils, and to a lesser extent mononuclear phagocytes and T cells</td><td colspan="1" rowspan="1">614172 (MonoMAC syndrome, Emberger syndrome)</td><td colspan="1" rowspan="1">AD (HI)</td><td colspan="1" rowspan="1">Aspergillosis, cryptococcosis, histoplasmosis, coccidioidomycosis, blastomycosis, PJP</td><td colspan="1" rowspan="1">Viral and NTM infections, PAP, MDS, leukaemia, lymphedema</td><td colspan="1" rowspan="1">Decreased monocyte and DC counts, neutrophil granule abnormalities</td></tr></tbody></table><table-wrap-foot><p>An expanded version of Table&#160;<xref rid="Tab2" ref-type="table">2</xref> is presented in Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>. AD, autosomal dominant; APECED, autoimmune polyendocrinopathy&#8211;candidiasis&#8211;ectodermal dystrophy; AR, autosomal recessive; CGD, chronic granulomatous disease; CMC, chronic mucocutaneous candidiasis; CNS, central nervous system; DC, dendritic cell; DN, dominant negative; eTAC, extrathymic AIRE-expressing cell; GOF, gain of function; HI, haploinsufficiency; HIES, hyper-IgE syndrome; IBD, inflammatory bowel disease; IFN, interferon; LOF, loss of function; MDS, myelodysplastic syndrome; MSMD, Mendelian susceptibility to mycobacterial disease; mTEC, medullary thymic epithelial cell; NTM, non-tuberculous mycobacteria; OMIM, Online Mendelian Inheritance in Man; PAP, pulmonary alveolar proteinosis; PBMC, peripheral blood mononuclear cell; PJP, <italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia; T<sub>H</sub>17, T helper 17.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Key FDA-approved immune-targeted biologics associated with the development of human fungal infections</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Molecular target</th><th colspan="1" rowspan="1">Name (and type) of biologic</th><th colspan="1" rowspan="1">Approved indications</th><th colspan="1" rowspan="1">Fungal infection susceptibility</th><th colspan="1" rowspan="1">Risk of fungal infection (mean frequency)</th><th colspan="1" rowspan="1">Non-fungal infection susceptibility</th><th colspan="1" rowspan="1">Antifungal immunological defects (when known)</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">TNF</td><td colspan="1" rowspan="1">Infliximab (mouse&#8211;human chimeric IgG1&#954; mAb)</td><td rowspan="4" colspan="1">RA, AS, psoriasis, IBD</td><td rowspan="2" colspan="1">Histoplasmosis, coccidioidomycosis, blastomycosis, PJP</td><td rowspan="2" colspan="1">Moderate/high</td><td rowspan="4" colspan="1">Mycobacterial infections (including disseminated TB)</td><td rowspan="4" colspan="1">Impaired IFN&#947; production and granuloma formation; impaired phagocyte trafficking and function</td></tr><tr><td colspan="1" rowspan="1">Etanercept (p75 TNF soluble receptor fused to the Fc portion of IgG1)</td></tr><tr><td colspan="1" rowspan="1">Adalimumab (humanized IgG1&#954; mAb)</td><td rowspan="2" colspan="1">Mucosal candidiasis, invasive candidiasis, aspergillosis, phaeohyphomycosis</td><td rowspan="2" colspan="1">Low (&lt;5%)</td></tr><tr><td colspan="1" rowspan="1">Golimumab (humanized IgG1&#954; mAb)</td></tr><tr><td colspan="1" rowspan="1">CD52</td><td colspan="1" rowspan="1">Alemtuzumab (humanized IgG1&#954; mAb)</td><td colspan="1" rowspan="1">MS, CLL</td><td colspan="1" rowspan="1">Cryptococcosis, PJP, mucosal candidiasis</td><td colspan="1" rowspan="1">Moderate/high</td><td colspan="1" rowspan="1">Herpetic infections, CMV infection, toxoplasmosis, nocardiosis, pneumonias</td><td colspan="1" rowspan="1">Prolonged and profound T lymphocytopenia</td></tr><tr><td rowspan="2" colspan="1">IL-17A</td><td colspan="1" rowspan="1">Ixekizumab (humanized IgG4 mAb)</td><td rowspan="7" colspan="1">Psoriasis, AS, IBD</td><td rowspan="7" colspan="1">Mucosal candidiasis</td><td rowspan="7" colspan="1">Low/moderate (~2&#8211;12% depending on the biologic)</td><td rowspan="7" colspan="1">None</td><td rowspan="7" colspan="1">Impaired IL-17 cellular responses</td></tr><tr><td colspan="1" rowspan="1">Secukinumab (humanized IgG1&#954; mAb)</td></tr><tr><td colspan="1" rowspan="1">IL-17RA</td><td colspan="1" rowspan="1">Brodalumab (humanized IgG2 mAb)</td></tr><tr><td colspan="1" rowspan="1">IL-12p40</td><td colspan="1" rowspan="1">Ustekinumab (humanized IgG1&#954; mAb)</td></tr><tr><td rowspan="3" colspan="1">IL-23p19</td><td colspan="1" rowspan="1">Risankizumab (humanized IgG1&#954; mAb)</td></tr><tr><td colspan="1" rowspan="1">Guselkumab (humanized IgG1&#955; mAb)</td></tr><tr><td colspan="1" rowspan="1">Tildrakizumab (humanized IgG1&#954; mAb)</td></tr><tr><td colspan="1" rowspan="1">JAK1/2/3</td><td colspan="1" rowspan="1">Ruxolitinib, tofacitinib, baricitinib, upadacitinib, fedratinib (kinase inhibitors)</td><td colspan="1" rowspan="1">MF, PV, GvHD, RA, IBD</td><td colspan="1" rowspan="1">Histoplasmosis, coccidioidomycosis, cryptococcosis, talaromycosis, PJP, aspergillosis</td><td colspan="1" rowspan="1">Moderate/high</td><td colspan="1" rowspan="1">Herpetic infections, CMV infection, mycobacterial infections</td><td colspan="1" rowspan="1">Impaired IFN&#947; and IFN&#955; responses, impaired lymphocyte and macrophage activation, lymphopenia</td></tr><tr><td colspan="1" rowspan="1">BTK</td><td colspan="1" rowspan="1">Ibrutinib, acalabrutinib, zanubrutinib (kinase inhibitors)</td><td colspan="1" rowspan="1">CLL, MZL, MCL, WM, GvHD</td><td colspan="1" rowspan="1">Aspergillosis (with CNS involvement), mucormycosis, cryptococcosis, blastomycosis, PJP</td><td colspan="1" rowspan="1">Moderate/high</td><td colspan="1" rowspan="1">Viral and bacterial infections</td><td colspan="1" rowspan="1">Impaired myeloid phagocyte activation and function</td></tr><tr><td colspan="1" rowspan="1">PI3K (p110&#948;)</td><td colspan="1" rowspan="1">Idelalisib (kinase inhibitor)</td><td colspan="1" rowspan="1">CLL, lymphomas</td><td colspan="1" rowspan="1">PJP</td><td colspan="1" rowspan="1">Moderate (~5&#8211;10%)</td><td colspan="1" rowspan="1">CMV infection, pneumonias</td><td colspan="1" rowspan="1">Impaired T cell activation</td></tr></tbody></table><table-wrap-foot><p>An expanded version of Table&#160;<xref rid="Tab3" ref-type="table">3</xref> is presented in Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">3</xref>. AS, ankylosing spondylitis; BTK, Bruton&#8217;s tyrosine kinase; CLL, chronic lymphocytic leukaemia; CMV, cytomegalovirus; CNS, central nervous system; GvHD, graft-versus-host disease; IBD, inflammatory bowel disease; IFN, interferon; mAb, monoclonal antibody; MCL, mantle-cell lymphoma; MF, myelofibrosis; MS, multiple sclerosis; MZL, marginal zone lymphoma; PJP, <italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia; PV, polycythaemia vera; RA, rheumatoid arthritis; TB, tuberculosis; TNF, tumour necrosis factor; WM, Waldenstr&#246;m macroglobulinaemia.</p></table-wrap-foot></table-wrap></p><sec id="Sec2"><boxed-text position="float" orientation="portrait"><label>Box 1 <italic toggle="yes">Candida auris</italic></label><p id="Par5">Since 2009, when it was initially identified in Japan, <italic toggle="yes">Candida auris</italic> has rapidly spread across six continents, causing multiple outbreaks of skin colonization and subsequent life-threatening bloodstream infections in vulnerable patients; <italic toggle="yes">C. auris</italic> accounts for up to 30% of cases of candidaemia in certain health care settings<sup><xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR185">185</xref>,<xref ref-type="bibr" rid="CR186">186</xref></sup>. <italic toggle="yes">C. auris</italic> is a major threat to public health owing to its unique propensity for long-term skin colonization, antimicrobial resistance and high person-to-person transmissibility within health care facilities, leading the US Centers for Disease Control and Prevention to designate it as an urgent threat in 2019 (ref. <xref ref-type="bibr" rid="CR187">187</xref>). The predilection of <italic toggle="yes">C. auris</italic> to colonize the skin, which distinguishes it from <italic toggle="yes">Candida albicans</italic> and other <italic toggle="yes">Candida</italic> species that reside within the gastrointestinal tract, has been verified both ex vivo in human and pig skin models and in vivo in mouse skin, where it establishes long-term residence within deep skin tissue and hair follicles<sup><xref ref-type="bibr" rid="CR188">188</xref>,<xref ref-type="bibr" rid="CR189">189</xref></sup>. <italic toggle="yes">C. auris</italic> has structurally unique mannoproteins compared with other <italic toggle="yes">Candida</italic> species, and its immune recognition by human circulating mononuclear cells and their induction of cytokine production is primarily mediated by complement receptor&#160;3 and the mannose receptor, not dectin&#160;1 (ref. <xref ref-type="bibr" rid="CR190">190</xref>). In a mouse model of skin colonization, IL-17A and IL-17F, but not IL-22, produced by innate and adaptive lymphocytes were crucial for curtailing <italic toggle="yes">C. auris</italic> skin colonization<sup><xref ref-type="bibr" rid="CR189">189</xref></sup>, and chlorhexidine application ameliorated fungal burden<sup><xref ref-type="bibr" rid="CR189">189</xref></sup>, which is in keeping with a similar finding in human patients<sup><xref ref-type="bibr" rid="CR185">185</xref></sup>. In invasive candidiasis in mice, <italic toggle="yes">C. auris</italic> is less lethal than <italic toggle="yes">Candida albicans</italic><sup><xref ref-type="bibr" rid="CR189">189</xref>&#8211;<xref ref-type="bibr" rid="CR191">191</xref></sup>, yet neutrophils have been shown to be poorly recruited to sites of <italic toggle="yes">C.&#160;auris</italic> infection and to ineffectively produce neutrophil extracellular traps and kill <italic toggle="yes">C. auris</italic> relative to <italic toggle="yes">C.&#160;albicans</italic>, which suggests that <italic toggle="yes">C. auris</italic> has specific immune-evading properties that are driven by its unique mannoprotein structure<sup><xref ref-type="bibr" rid="CR191">191</xref></sup>. A better understanding of the fungal and host determinants of the unique skin tropism of <italic toggle="yes">C. auris</italic> may help to develop improved preventive and therapeutic strategies against this pathogen.</p></boxed-text></sec></sec><sec id="Sec3"><title>Mucocutaneous candidiasis</title><p id="Par6"><italic toggle="yes">Candida</italic> species (primarily <italic toggle="yes">Candida albicans</italic>) are commensal yeasts of the gastrointestinal and reproductive tracts in most humans. When disruptions to the immune system and/or the resident microbiota occur, <italic toggle="yes">Candida</italic> can cause opportunistic infections at mucocutaneous or deep-seated anatomical sites, which have different requirements for immune defence<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Specifically, whereas innate and adaptive lymphocytes mediate protection against mucocutaneous candidiasis, myeloid phagocytes are crucial for protection against invasive candidiasis<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Indeed, patients with HIV/AIDS, having low CD4<sup>+</sup> T cell counts, are at risk of developing mucocutaneous candidiasis, whereas patients with neutropenia are susceptible to invasive candidiasis, but not vice versa<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p id="Par7">Mucocutaneous candidiasis presents clinically as oropharyngeal candidiasis (OPC), oesophageal candidiasis or vulvovaginal candidiasis (VVC). A major breakthrough in the field of fungal immunology has been the discovery that IL-17 receptor (IL-17R) signalling is a crucial defence pathway against mucocutaneous candidiasis<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> (Fig.&#160;<xref rid="Fig1" ref-type="fig">1a</xref>). Mice and humans with complete genetic deficiencies in IL-17RA, IL-17RC or their adaptor protein ACT1 (also known as TRAF3IP2) are highly susceptible to fully penetrant&#160;<xref rid="Glos4" ref-type="list">chronic mucocutaneous candidiasis</xref> (CMC)<sup><xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref></sup>. Several other CMC-manifesting inborn errors of immunity exhibit varying degrees of&#160;impaired IL-17&#160;cellular responses&#160;and/or decreased frequencies of circulating T helper 17 (T<sub>H</sub>17) cells<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup> (Table&#160;<xref rid="Tab2" ref-type="table">2</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>). Moreover, administration of IL-17 pathway-targeting biologics for the treatment of psoriasis has been associated with mild, treatment-responsive OPC, with a mean frequency of ~2&#8211;12%, depending on the biologic agent<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup> (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). The relatively low frequency of OPC and the lack of CMC in these patients likely reflect that mucosal IL-17 responses are not completely inhibited by these biologics and are consistent with the notion that profound and sustained inhibition of the IL-17 pathway is required for the development of mucosal fungal disease<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Host defence against <italic toggle="yes">Candida</italic> at the oral mucosal interface.</title><p><bold>a</bold>,&#160;Protective responses to <italic toggle="yes">Candida</italic> at mucosal surfaces are mediated by IL-17 and IL-22 produced by T helper 17 (T<sub>H</sub>17) cells, CD8<sup>+</sup> T cells, type 3 innate lymphoid&#160;cells (ILC3s) and &#947;&#948; T cells. T<sub>H</sub>17 cell differentiation depends on signal transducer and activator of transcription&#160;3 (STAT3)-mediated retinoic acid receptor-related orphan receptor-&#947;t (ROR&#947;t) induction downstream of signalling through IL-6 receptor (IL-6R) and IL-23R, which is defective in individuals with mutations in <italic toggle="yes">RORC</italic> (which encodes ROR&#947;t), <italic toggle="yes">STAT3</italic> or <italic toggle="yes">ZNF341</italic> (which regulates STAT3 expression and function), making them highly susceptible to chronic mucocutaneous candidiasis (CMC). T<sub>H</sub>17 cells produce IL-17A, IL-17F and IL-22. IL-17A, IL-17F and IL-17A&#8211;IL-17F bind to IL-17R, consisting of IL-17RA and IL-17RC, on suprabasal epithelial cells, which leads to the activation of ACT1 and induces the production of antimicrobial peptides (AMPs; such as &#946;-defensin&#160;3 and S100A8/S100A9) that restrict <italic toggle="yes">Candida</italic> growth. CMC also develops in patients with mutations in <italic toggle="yes">IL17F</italic>, <italic toggle="yes">IL17RA</italic>, <italic toggle="yes">IL17RC</italic> or <italic toggle="yes">TRAF3IP2</italic> (which encodes ACT1), and in patients with thymoma or <italic toggle="yes">AIRE</italic> mutations, both of which are associated with autoantibodies to IL-17 and/or IL-22. Furthermore, mild oral thrush can develop in a subset of patients receiving IL-17 pathway-targeted biologics such as those inhibiting IL-17A, IL-17RA, IL-12p40 (not shown) or IL-23 (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). IL-22 produced by T<sub>H</sub>17 cells, CD8<sup>+</sup> T cells, ILC3s and &#947;&#948; T cells binds to the IL-22 receptor consisting of IL-22RA1 and IL-10RB on basal epithelial cells, which activates STAT3 and facilitates epithelial cell proliferation and repair, thereby enabling the replenishment and responsiveness of the IL-17R-expressing suprabasal epithelial cell layer. <bold>b</bold>, Mucosal type II interferonopathy. In the setting of autoimmunity caused by autoimmune regulator (AIRE) deficiency, mucosal CD4<sup>+</sup> T<sub>H</sub>1 cells and CD8<sup>+</sup> T cells locally produce increased levels of interferon-&#947; (IFN&#947;), which binds to the IFN&#947; receptor consisting of IFNGR1 and IFNGR2 on epithelial cells, activates STAT1 and impairs oral epithelial barrier integrity. This leads to increased susceptibility to oropharyngeal candidiasis. JAK, Janus kinase; TYK2, tyrosine kinase 2.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e1478" position="float" orientation="portrait" xlink:href="41577_2022_826_Fig1_HTML.jpg"/></fig></p><p id="Par8">At the cellular level, IL-17A and IL-17F are produced by &#945;&#946; T cells, &#947;&#948; T cells and type&#160;3 innate lymphoid cells during OPC<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup> (Fig.&#160;<xref rid="Fig1" ref-type="fig">1a</xref>). The <italic toggle="yes">C. albicans</italic> toxin&#160;<xref rid="Glos5" ref-type="list">candidalysin</xref>, Langerin-expressing dendritic cells (DCs) and microbiota-derived retinoic acid prime <xref rid="Glos6" ref-type="list">natural T<sub>H</sub>17 cell</xref> responses initially, followed by <italic toggle="yes">Candida</italic>-specific T<sub>H</sub>17 cell generation that is facilitated by antigen presentation by CCR2<sup>+</sup> monocyte-derived DCs<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref></sup>. By contrast, the <italic toggle="yes">C. albicans</italic> lipase Lip2 was recently shown to suppress IL-17 responses by &#947;&#948; T cells indirectly through inhibition of IL-23 production by tissue-resident DCs<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Notably, mucosal CD8<sup>+</sup> T cells, &#947;&#948; T cells and type&#160;3 innate lymphoid cells can compensate for IL-17 production when T<sub>H</sub>17 cells are absent, as <italic toggle="yes">Cd4</italic><sup>&#8722;/&#8722;</sup> mice are not susceptible to OPC in primary or recall models and patients with loss-of-expression <italic toggle="yes">CD4</italic> mutations or idiopathic CD4 lymphocytopenia who lack CD4<sup>+</sup> T cells are resistant to CMC<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR26">26</xref></sup>. Thus, decreased levels of circulating T<sub>H</sub>17 cells may not in isolation be a reliable immunological biomarker for risk assessment of human CMC, and the direct evaluation of global mucosal IL-17 responses may be needed to determine the mechanisms of CMC.</p><p id="Par9">Following IL-17RA&#8211;IL-17RC engagement on epithelial cells by IL-17A and/or IL-17F, the generation of antimicrobial peptides restricts local <italic toggle="yes">Candida</italic> growth and epithelial invasion<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. Furthermore, the epithelial cell pattern recognition receptor EPHA2 recognizes fungal &#946;-glucan, activates STAT3 and epidermal growth factor receptor&#160;2 (EGFR2) signalling, and boosts mucosal IL-17 responses likely through priming the production of IL-1&#945;/IL-1&#946; during mucosal infection, which facilitates natural T<sub>H</sub>17 cell proliferation<sup><xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR27">27</xref></sup>. IL-22, another type&#160;17 cytokine produced by lymphocytes, binds to IL-22RA1&#8211;IL-10RB on epithelial cells, activates STAT3 and promotes epithelial cell proliferation and repair, thereby replenishing IL-17R-expressing epithelial cells and enabling their responsiveness to IL-17A and IL-17F<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> (Fig.&#160;<xref rid="Fig1" ref-type="fig">1a</xref>).</p><p id="Par10">Whereas IL-17 is protective during OPC, in certain settings &#8212; such as the autoimmune syndrome of AIRE deficiency, which features an incompletely penetrant association between CMC and IL-17-neutralizing autoantibodies<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR29">29</xref>,<xref ref-type="bibr" rid="CR30">30</xref></sup> &#8212; excessive interferon-&#947; (IFN&#947;) production by mucosal &#945;&#946; T cells can promote OPC susceptibility by driving epithelial barrier disruption, which is ameliorated by IFN&#947; inhibition or inhibition of JAK&#8211;STAT signalling downstream of the IFN&#947; receptor<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> (Fig.&#160;<xref rid="Fig1" ref-type="fig">1b</xref>). This finding suggests that OPC susceptibility could be classified across a spectrum that encompasses impaired type&#160;17 mucosal defences and/or immunopathology-promoting type&#160;1 mucosal inflammation. Indeed, the recent discovery of CMC-manifesting inborn errors of immunity with intact or enhanced IL-17 responses in the setting of autoinflammation or autoimmunity (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>) may uncover additional conditions in which OPC may be driven by mucosal immunopathology rather than by impaired host resistance. Notably, in patients with <italic toggle="yes">STAT1</italic> gain-of-function mutations, who universally develop CMC associated with decreased circulating T<sub>H</sub>17 cells and increased IFN&#947; cellular responses, pharmacological JAK&#8211;STAT inhibition ameliorates CMC, pointing to a beneficial immunotherapeutic strategy in this setting<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>.</p><p id="Par11">VVC occurs at least once in ~75% of healthy women during their reproductive years. An estimated 6&#8211;9% of these women have more than three recurrent episodes of VVC per year, a pervasive condition termed &#8216;recurrent VVC&#8217;. As opposed to OPC, VVC is characterized by maladaptive, fungus-driven, neutrophil-associated inflammation with excessive local production of alarmins and pro-inflammatory cytokines<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. Correspondingly, genetic polymorphisms in <italic toggle="yes">NLRP3, SIGLEC15, IDO1</italic> and other genes that augment the vaginal inflammatory milieu are associated with a greater risk of recurrent VVC<sup><xref ref-type="bibr" rid="CR33">33</xref>,<xref ref-type="bibr" rid="CR34">34</xref></sup>. Interestingly, whereas patients with HIV/AIDS and patients receiving IL-17 pathway-targeted biologics are at increased risk of developing OPC, they are not at risk of developing VVC, in agreement with the finding that IL-17R deficiency does not impair fungal control during mouse VVC<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>. By contrast, antibiotics predispose women to VVC, but not OPC, which indicates that the vaginal microbiota has a role in restricting local growth of <italic toggle="yes">Candida</italic> through poorly defined mechanisms that require further investigation<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Thus, the oral and vaginal mucosal immune responses to <italic toggle="yes">C. albicans</italic> are distinct. Importantly, VVC has been a target disease for protection with the <italic toggle="yes">C. albicans</italic>&#160;<xref rid="Glos7" ref-type="list">agglutinin-like sequence&#160;3</xref> (Als3)-based vaccine, which was shown to be immunogenic and efficacious in mouse models of VVC and in women with recurrent VVC<sup><xref ref-type="bibr" rid="CR37">37</xref>,<xref ref-type="bibr" rid="CR38">38</xref></sup>. The Als3-based vaccine is the only fungal vaccine that has thus far exhibited clinical protection in humans<sup><xref ref-type="bibr" rid="CR37">37</xref></sup> (Box&#160;<xref rid="Sec4" ref-type="sec">2</xref>).</p><p id="Par12"><italic toggle="yes">C. albicans</italic> is effectively controlled at the cutaneous barrier by an IL-17-enforced neuroimmune axis and rarely causes clinical skin disease in humans<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Specifically, cutaneous <italic toggle="yes">C. albicans</italic> infection in mice promotes the activation of TRPV1<sup>+</sup> sensory neurons expressing the neuropeptide calcitonin gene-related peptide, which is both necessary and sufficient to drive protective IL-17 responses<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>. These neuroimmune findings paved the way for the recent demonstration that gut fungi drive IL-17-dependent neuroimmune modulation of mouse behaviour<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>, further expanding our knowledge of the essential roles of neuroimmune circuits in tissue homeostasis and immunity (reviewed in ref. <xref ref-type="bibr" rid="CR42">42</xref>).</p><sec id="Sec4"><boxed-text position="float" orientation="portrait"><label>Box 2 Fungal vaccines</label><p id="Par13">Despite the substantial global burden, cost, morbidity and mortality associated with opportunistic fungal infections, no human fungal vaccine has been licensed to date. Major challenges in developing human fungal vaccines include concerns about their safety and efficacy in the immunocompromised patients who are typically at risk of serious fungal disease and difficulties in attracting pharmaceutical industry interest. Promising results have been obtained with various vaccine formulations (for example, killed or live attenuated fungi, crude fungal extracts, recombinant fungal subunits and nucleic acids encoding fungal antigens) in animal models of candidiasis, aspergillosis, cryptococcosis, coccidioidomycosis, histoplasmosis and blastomycosis (reviewed elsewhere<sup><xref ref-type="bibr" rid="CR192">192</xref>,<xref ref-type="bibr" rid="CR193">193</xref></sup>). Among these, only three have reached human clinical trials. The first-in-human fungal vaccine was a formalin-killed spherule vaccine for coccidioidomycosis, which showed no efficacy and caused topical and systemic adverse reactions in a phase&#160;III trial in the 1980s<sup><xref ref-type="bibr" rid="CR194">194</xref></sup>. The other two are recombinant <italic toggle="yes">Candida</italic> vaccines. The first vaccine, termed &#8216;PEV7&#8217;, was based on recombinant <italic toggle="yes">C. albicans</italic> secreted aspartic protease&#160;2 (Sap2) formulated with influenza virosomes. It protected rats from vulvovaginal candidiasis, and a phase&#160;I clinical trial found it to be safe and immunogenic, but no further clinical development has occurred since 2012 (ref. <xref ref-type="bibr" rid="CR195">195</xref>). The second vaccine, termed &#8216;NDV-3&#8217;, is based on recombinant amino terminus of <italic toggle="yes">C. albicans</italic> agglutinin-like sequence&#160;3 (Als3) formulated with alum adjuvant. NDV-3 protected mice against mucosal and invasive candidiasis caused by several <italic toggle="yes">Candida</italic> species, including <italic toggle="yes">C. auris</italic>, cross-protected against <italic toggle="yes">Staphylococcus aureus</italic> owing to structural homology between Als3 and an <italic toggle="yes">S. aureus</italic> clumping factor, and stimulated T helper 1 (T<sub>H</sub>1) cell, T<sub>H</sub>17 cell and B cell responses<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR196">196</xref>&#8211;<xref ref-type="bibr" rid="CR198">198</xref></sup>. In a phase&#160;I clinical trial, NDV-3 was safe and immunogenic, eliciting antigen-specific IgA and IgG and T<sub>H</sub>1 cell- and T<sub>H</sub>17 cell-associated cytokine responses<sup><xref ref-type="bibr" rid="CR199">199</xref></sup>. In a recent double-blind, placebo-controlled phase&#160;Ib/IIa trial involving 188 women with recurrent vulvovaginal candidiasis, the vaccine was safe and immunogenic, and it decreased the frequency of vulvovaginal candidiasis in women older than 40&#160;years<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>. A forthcoming goal is to test the efficacy of the vaccine in preventing candidaemia in high-risk patients in intensive care. Moving forward, harnessing fungal cell wall constituents as adjuvants and exploiting conserved fungal epitopes to induce cross-protection against multiple fungi are exciting strategies towards pan-fungal vaccine development<sup><xref ref-type="bibr" rid="CR192">192</xref></sup>. For example, vaccine delivery of the conserved <italic toggle="yes">Blastomyces</italic>-derived chaperone calnexin in glucan particles protected mice against endemic dimorphic fungi, aspergillosis, chromoblastomycosis and <italic toggle="yes">Pseudogymnoascus destructans</italic>, which causes the life-threatening white-nose syndrome in bats<sup><xref ref-type="bibr" rid="CR146">146</xref>,<xref ref-type="bibr" rid="CR200">200</xref>,<xref ref-type="bibr" rid="CR201">201</xref></sup>.</p></boxed-text></sec></sec><sec id="Sec5"><title>Invasive candidiasis</title><p id="Par14">Invasive candidiasis is a leading cause of nosocomial bloodstream infection in higher-income countries, with mortality that can exceed 40% despite treatment<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. It typically occurs in patients&#160;who are critically ill in whom <italic toggle="yes">Candida</italic> transitions from a commensal pathogen to an opportunistic pathogen by translocating into the bloodstream and seeding deep-seated organs such as liver, spleen and kidney<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Although <italic toggle="yes">C. albicans</italic> is most often responsible for invasive candidiasis, <italic toggle="yes">Candida glabrata</italic>, <italic toggle="yes">Candida tropicalis</italic> and <italic toggle="yes">Candida parapsilosis</italic> also cause disease with increasing frequency, and the multidrug-resistant <italic toggle="yes">Candida auris</italic> has spread rapidly worldwide in recent years<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> (Box&#160;<xref rid="Sec2" ref-type="sec">1</xref>).</p><p id="Par15">Certain iatrogenic factors are typically associated with the development of invasive candidiasis in humans<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Broad-spectrum antibiotics induce gut dysbiosis, impair lymphocyte-mediated IL-17A-dependent and granulocyte&#8211;macrophage colony-stimulating factor (GM-CSF)-dependent intestinal immune responses and inhibit the local generation of antimicrobial peptides, thereby enhancing <italic toggle="yes">Candida</italic> gut colonization and invasion<sup><xref ref-type="bibr" rid="CR43">43</xref>,<xref ref-type="bibr" rid="CR44">44</xref></sup>; this antibiotic-induced susceptibility was ameliorated by IL-17A or GM-CSF immunotherapy in a mouse model of invasive candidiasis<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Central venous catheters or chemotherapy-induced mucositis and surgery, which breach the integrity of the cutaneous barrier or the intestinal barrier, respectively, can allow <italic toggle="yes">Candida</italic> to translocate into the bloodstream<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Iatrogenic immunosuppression (for example, chemotherapy-induced neutropenia or use of corticosteroids), which impairs protective myeloid phagocyte-dependent antifungal responses, facilitates the invasion of deep-seated organs by <italic toggle="yes">Candida</italic><sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. Rapid neutrophil influx and activation in <italic toggle="yes">Candida</italic>-infected tissues are crucial for effective host defence in mice, in agreement with the profound susceptibility of humans with neutropenia to invasive candidiasis<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p id="Par16">The CLRs dectin&#160;1 (also known as CLEC7A), dectin&#160;2 (also known as CLEC6A) and dectin&#160;3 (also known as CLEC4D) recognize <italic toggle="yes">Candida</italic> &#946;-glucans and &#945;-mannans and signal through the kinase SYK and the CARD9&#8211;MALT1&#8211;BCL-10 signalling complex to activate NF-&#954;B, collectively promoting T<sub>H</sub>17 cell development and pro-inflammatory cytokine production<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. CARD9 deficiency is so far the only known inborn error of immunity that predisposes to both mucosal candidiasis and invasive candidiasis, with a unique tropism for the central nervous system (CNS)<sup><xref ref-type="bibr" rid="CR45">45</xref></sup> (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Mechanistically, in response to fungal candidalysin, CNS-resident microglia produce IL-1&#946; in a CARD9-dependent manner, which mediates protective neutrophil recruitment to the CNS through CXCL1&#8211;CXCR2-dependent chemotaxis<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. In line with this, pharmacological blockade of the CLR&#8211;SYK&#8211;CARD9 signalling axis with the SYK inhibitor fostamatinib has been associated with opportunistic fungal infections (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">3</xref>).</p><p id="Par17">Invasive candidiasis also occurs in a small proportion of patients with severe congenital neutropenia syndromes or inborn errors of immunity that affect the phagocyte oxidative burst, such as complete myeloperoxidase deficiency or chronic granulomatous disease (caused by mutations in NADPH oxidase complex subunits)<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> (Table&#160;<xref rid="Tab2" ref-type="table">2</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>). Although invasive candidiasis is not a recognized phenotype of inherited deficiency of complement component C5 (ref.&#160;<xref ref-type="bibr" rid="CR9">9</xref>), acute pharmacological inhibition of C5a with eculizumab increases susceptibility to <italic toggle="yes">Candida</italic> infection, which suggests a crucial role of complement activation in mounting innate antifungal responses in vulnerable patients<sup><xref ref-type="bibr" rid="CR47">47</xref></sup> (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">3</xref>).</p><p id="Par18">Within <italic toggle="yes">Candida</italic>-infected tissues, an intricate intercellular crosstalk orchestrates the candidacidal activity of neutrophils. Specifically, Ly6C<sup>+</sup> inflammatory monocytes and monocyte-derived DCs produce IL-15 and IL-23, respectively, which in turn activate natural killer cells to release GM-CSF, which primes neutrophils to kill <italic toggle="yes">Candida</italic><sup><xref ref-type="bibr" rid="CR48">48</xref>,<xref ref-type="bibr" rid="CR49">49</xref></sup>. Consistent with these results, a phase&#160;IV clinical trial showed that GM-CSF administration in allogeneic HSCT recipients decreased the incidence of invasive candidiasis and associated mortality<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. Neutrophil reactive oxygen species (ROS)-dependent killing of <italic toggle="yes">Candida</italic> involves dectin&#160;1-dependent metabolic rewiring of neutrophils and dectin&#160;1-mediated activation of the calcineurin&#8211;NFAT and MAC1 (CD11B&#8211;CD18)&#8211;VAV&#8211;PKC&#948; pathways<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR51">51</xref></sup>.&#160;<xref rid="Glos8" ref-type="list">Uraemia</xref>, which is another known risk factor for human invasive candidiasis, impairs neutrophil ROS production and <italic toggle="yes">Candida</italic> killing by reducing GLUT1-dependent glucose uptake through hyperactivation of glycogen synthase kinase-3&#946; (GSK3&#946;)<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. Pharmacological inhibition of GSK3&#946; restores neutrophil candidacidal activity in mice and humans with uraemia, pointing to a potential therapeutic intervention in this setting<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>.</p><p id="Par19">Although neutrophils are protective during invasive candidiasis, their excessive accumulation and activation may also have detrimental effects, as seen in patients with neutropenia upon neutrophil recovery. Corticosteroids ameliorate inflammation and clinical symptoms in this setting, but certain immunopathogenic factors have been delineated in mice and humans &#8212; for example, the chemokine receptor CCR1, the CLR DNGR1, the endoribonuclease MCPIP1, the secreted growth factor progranulin and IFN&#947; &#8212; that show promise for eventually developing more selective therapeutic approaches<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR53">53</xref>&#8211;<xref ref-type="bibr" rid="CR57">57</xref></sup>. Moreover, immunopathology during renal candidiasis can be ameliorated through activation of the IL-17-dependent&#160;<xref rid="Glos9" ref-type="list">kallikrein&#8211;kinin system</xref>, which prevents renal tubular cell apoptosis and preserves kidney function<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. Administration of bradykinin combined with antifungal therapy provided a synergistic survival benefit during mouse kidney infection with <italic toggle="yes">Candida</italic><sup><xref ref-type="bibr" rid="CR58">58</xref></sup>, raising the possibility that the antihypertensive class of angiotensin-converting enzyme inhibitors, which increase bradykinin levels, might have protective effects in this context.</p><p id="Par20">In mouse invasive candidiasis, in addition to neutrophils, CCR2<sup>+</sup> infiltrating monocytes and CX3CR1<sup>+</sup> tissue-resident macrophages also contribute to protective immunity in the kidney and CNS by promoting <italic toggle="yes">Candida</italic> uptake and killing<sup><xref ref-type="bibr" rid="CR59">59</xref>,<xref ref-type="bibr" rid="CR60">60</xref></sup>. Importantly, beyond acute experimental candidiasis, monocytes and macrophages also protect against systemic <italic toggle="yes">C. albicans</italic> reinfection through a process termed &#8216;<xref rid="Glos10" ref-type="list">trained immunity</xref>&#8217;. Mechanistically, protection in this setting is conferred through activation of dectin&#160;1, RAF1, AKT, mTOR and hypoxia-inducible factor 1&#945; (HIF1&#945;) signalling that drives epigenetic reprogramming and cellular metabolic rewiring of monocytes and macrophages, with a switch to aerobic glycolysis<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR61">61</xref></sup>. By contrast, activation of macrophage JNK1 increases mortality during invasive candidiasis by downregulating expression of the CLR CD23 (also known as Fc&#949;RII) and impairing macrophage production of nitric oxide<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>. Thus, whereas JNK1 deficiency predisposes to CMC in humans (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>), it may protect against invasive candidiasis<sup><xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>. Interestingly, although patients with humoral defects are not considered at risk of bloodstream candidiasis, mouse gut-educated IgA<sup>+</sup> meningeal plasma cells located near dural venous sinuses were recently shown to entrap <italic toggle="yes">C. albicans</italic> and restrict its spread in the CNS, uncovering a potential role for humoral immunity in protection against invasive candidiasis at this anatomical site<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>.</p><p id="Par21">Population studies in patients who are critically ill&#160;have shown that genetic polymorphisms in genes including <italic toggle="yes">TLR1</italic>, <italic toggle="yes">CXCR1</italic>, <italic toggle="yes">CX3CR1</italic>, <italic toggle="yes">STAT1</italic> and <italic toggle="yes">TAGAP</italic>, many of which have shown corroborating protective effects in mouse models of invasive candidiasis, are associated with greater risk of invasive candidiasis and/or worse outcome after infection. Notably, the combined presence of certain polymorphisms can increase susceptibility to invasive candidiasis by up to ~20-fold<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR65">65</xref></sup>. Collectively, these findings may provide a foundation for the eventual development of immunogenomic approaches for personalized risk stratification, prophylaxis and prognostication in high-risk patients.</p></sec><sec id="Sec6"><title>Aspergillosis</title><p id="Par22">Aspergillosis is an opportunistic, life-threatening fungal infection that develops following inhalation of ubiquitous <italic toggle="yes">Aspergillus</italic> moulds (primarily <italic toggle="yes">Aspergillus fumigatus</italic>) in humans with numeric or functional deficits in myeloid phagocytes, such as individuals with neutropenia, who&#160;receive corticosteroids or who are HSCT recipients, and, recently, in patients with severe influenza or COVID-19 pneumonia<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR66">66</xref></sup> (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Humans continuously inhale <italic toggle="yes">Aspergillus</italic> conidia (2&#8211;3&#8201;&#956;m in diameter in the case of <italic toggle="yes">A. fumigatus</italic>), and an important immunological checkpoint involves preventing the formation of tissue-invasive filamentous hyphae in the respiratory tree. Myeloid phagocytes are necessary and sufficient to maintain this checkpoint as <italic toggle="yes">Rag2</italic><sup><italic toggle="yes">&#8722;/&#8722;</italic></sup><italic toggle="yes">Il2rg</italic><sup><italic toggle="yes">&#8722;/&#8722;</italic></sup> mice that lack innate and adaptive lymphocytes clear conidia without developing invasive disease<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>, similarly to humans with defects in lymphoid function or numbers<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Although lymphocytes seem to be redundant for protection against aspergillosis in hosts with intact myeloid cells, it is possible that adoptively transferred lymphocytes may provide benefit in hosts with an injured myeloid compartment<sup><xref ref-type="bibr" rid="CR68">68</xref>,<xref ref-type="bibr" rid="CR69">69</xref></sup>. <italic toggle="yes">Aspergillus</italic> also causes allergic disease and chronic cavitation in individuals with atopy and structural lung damage, respectively (reviewed in refs. <xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR71">71</xref>).</p><p id="Par23">A central theme of defence against inhaled <italic toggle="yes">Aspergillus</italic> is molecular and cellular redundancy in achieving sterilizing immunity and an essential role of intercellular crosstalk to regulate leukocyte infiltration and effector functions within the lung (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). In immunocompetent individuals, conidia are engulfed by alveolar macrophages<sup><xref ref-type="bibr" rid="CR72">72</xref></sup> and conidial germination within phagosomes triggers a pro-inflammatory cascade through dectin&#160;1-dependent recognition of &#946;-1,3-glucan<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>, which is exposed on the surface of the germinating conidia<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>. Moreover, exposure of fungal mannans engages soluble pentraxin&#160;2 (ref. <xref ref-type="bibr" rid="CR75">75</xref>) and pentraxin&#160;3 (ref. <xref ref-type="bibr" rid="CR76">76</xref>) and the CLRs dectin&#160;2 and dectin&#160;3, sequentially activating SYK, CARD9&#8211;MALT1&#8211;BCL-10, NF-&#954;B and the NLRP3 inflammasome, and thereby resulting in pro-inflammatory cytokine production<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. CLR-dependent activation of phospholipase-&#947; induces Ca<sup>2+</sup>&#8211;calcineurin phosphatase activity and nuclear translocation of the transcription factor NFAT<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. In addition to these immunostimulatory <italic toggle="yes">Aspergillus</italic> polysaccharides, conidial dihydroxynaphthalene melanin activates the CLR MelLec (also known as CLEC1A) and induces downstream signalling through an unknown pathway<sup><xref ref-type="bibr" rid="CR77">77</xref></sup>. The <italic toggle="yes">Aspergillus</italic> thaumatin-like protein CalA binds to epithelial and endothelial cells through &#945;5&#946;1 integrin&#160;to promote its internalization and spread, and antibody-mediated blockade of CalA ameliorates mortality in <italic toggle="yes">Aspergillus</italic>-infected mice<sup><xref ref-type="bibr" rid="CR78">78</xref></sup>.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Cellular crosstalk regulates antifungal innate immunity in the lung.</title><p><bold>a</bold>, Fungal recognition and epithelial cell&#8211;leukocyte crosstalk coordinate the recruitment of neutrophils and monocytes to the alveoli. Alveolar macrophages and lung-resident dendritic cells (DCs; not shown) engulf <italic toggle="yes">Aspergillus fumigatus</italic> conidia that reach the terminal airways, which are the site of gas exchange. Rapid release of IL-1&#945;/&#946; by macrophages and DCs stimulates the IL-1 receptor (IL-1R)&#8211;MYD88-dependent production of the neutrophil-recruiting chemokines CXCL1 and CXCL5 by lung epithelial cells. The release of CXCL2 by haematopoietic cells, including macrophages, through C-type lectin receptor (CLR)&#8211;CARD9 activation, and the rapid production of leukotriene B<sub>4</sub> (LTB4) and complement component C5a also contribute to sustained neutrophil recruitment. In addition, CCR2<sup>+</sup> circulating monocytes enter the lung parenchyma and differentiate into monocyte-derived DCs. Opsonization of <italic toggle="yes">A. fumigatus</italic> conidia by pentraxins enables their efficient uptake and killing by neutrophils. <bold>b</bold>, The recruited neutrophils and monocyte-derived DCs engulf conidia into phagolysosomes, which are the site of intracellular conidial killing. Both resident myeloid cells and infiltrating CCR2<sup>+</sup> monocytes produce type I interferon early in the response and regulate ensuing type III interferon release. Fungus-engaged neutrophils and monocyte-derived DCs secrete CXCL9 and CXCL10 (through CLR&#8211;CARD9&#8211;SYK and type I interferon-dependent pathways, respectively), which recruit CXCR3<sup>+</sup> plasmacytoid DCs (pDCs) to the lung. <bold>c</bold>, Innate crosstalk licenses the full spectrum of neutrophil antifungal activity. Conidial killing by neutrophils and monocyte-derived DCs is enhanced by the entry of CXCR3<sup>+</sup> pDCs and by type I and type III interferons that converge on signal transducer and activator of transcription&#160;1 (STAT1) signalling in neutrophils. Fungus-induced release of granulocyte&#8211;macrophage colony-stimulating factor (GM-CSF) also potentiates neutrophil antifungal properties by enhancing NADPH oxidase activity and the production of reactive oxygen species (ROS). In the context of blastomycosis, CCR6<sup>+</sup> innate lymphocytes and natural T helper 17 cells contribute to GM-CSF production during acute pulmonary infection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2260" position="float" orientation="portrait" xlink:href="41577_2022_826_Fig2_HTML.jpg"/></fig></p><p id="Par24">Among the inborn errors of immunity, aspergillosis is a signature infection of chronic granulomatous disease<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>, which highlights the importance of ROS generation in maintaining sterilizing lung immunity (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). <italic toggle="yes">Aspergillus</italic> hyphae induce neutrophil production of ROS through &#946;2 integrin and SYK<sup><xref ref-type="bibr" rid="CR79">79</xref></sup>, which triggers a regulated cell death process in <italic toggle="yes">Aspergillus</italic> that is opposed by the fungal anti-cell-death gene <italic toggle="yes">Afbir1</italic> (ref. <xref ref-type="bibr" rid="CR80">80</xref>). On the basis of the fact that IFN&#947; stimulates phagocyte ROS production, recombinant IFN&#947; has been approved for use as an immunotherapy to prevent invasive (including fungal) infections in patients with chronic granulomatous disease<sup><xref ref-type="bibr" rid="CR81">81</xref></sup>. In addition to licensing neutrophil fungicidal activity, ROS also regulate&#160;<xref rid="Glos11" ref-type="list">LC3-associated phagocytosis</xref>, an adjunctive mechanism of fungal clearance<sup><xref ref-type="bibr" rid="CR82">82</xref></sup>. <italic toggle="yes">Aspergillus</italic> conidial melanin hinders dectin&#160;1-dependent and SYK-dependent activation of LC3-associated phagocytosis in macrophages, and phagosomal removal of melanin enhances macrophage antifungal activity by increasing calcium flux through glycolysis<sup><xref ref-type="bibr" rid="CR83">83</xref></sup>.</p><p id="Par25">In pulmonary aspergillosis in mice, infiltrating neutrophils, Ly6C<sup>+</sup> inflammatory monocytes and CXCR3<sup>+</sup> plasmacytoid DCs are essential cellular effectors<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR84">84</xref></sup> (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). Rapid neutrophil influx depends on sequential IL-1R&#8211;MYD88 signalling-dependent release of CXCL1 and CXCL5 by the lung epithelium, including club cells<sup><xref ref-type="bibr" rid="CR85">85</xref>,<xref ref-type="bibr" rid="CR86">86</xref></sup>. Thereafter, CLR&#8211;CARD9-dependent signalling in haematopoietic cells, including macrophages, sustains pulmonary neutrophil influx through CXCL2 production, which is consistent with a model of sequential and compartment-specific regulation of pulmonary neutrophil recruitment in this context. In CARD9-deficient humans, aspergillosis is typically extrapulmonary, which supports the idea that CARD9-dependent and CARD9-independent pathways of neutrophil recruitment collaborate in the lung, but that CARD9 predominantly controls neutrophil recruitment to extrapulmonary sites of <italic toggle="yes">Aspergillus</italic> infection<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>. In addition to IL-1R&#8211;MYD88-dependent and CLR&#8211;CARD9-dependent leukocyte recruitment to the <italic toggle="yes">Aspergillus</italic>-infected lung, signalling through the RNA sensor MDA5&#8211;MAVS<sup><xref ref-type="bibr" rid="CR88">88</xref></sup> and leukotriene&#160;B<sub>4</sub> biosynthesis<sup><xref ref-type="bibr" rid="CR89">89</xref></sup> also contribute. Within the <italic toggle="yes">Aspergillus</italic>-infected lung, the lectin family member galectin&#160;3 increases neutrophil motility and facilitates neutrophil extravasation into bronchoalveolar air spaces<sup><xref ref-type="bibr" rid="CR90">90</xref></sup>.</p><p id="Par26">In addition to neutrophils, mononuclear phagocytes also promote pulmonary defences against <italic toggle="yes">Aspergillus</italic> both directly and indirectly by priming neutrophil effector functions. CCR2<sup>+</sup> lung-infiltrating monocytes differentiate into monocyte-derived DCs that engulf, inactivate and transport conidia to lung-draining lymph nodes<sup><xref ref-type="bibr" rid="CR67">67</xref>,<xref ref-type="bibr" rid="CR91">91</xref></sup>. CCR2<sup>+</sup> monocyte-derived DCs also produce type&#160;I interferons, which in turn control type&#160;III interferon production within the fungus-infected lung. Type&#160;I and type&#160;III interferon receptor engagement and STAT1 signalling are essential for host defence by enhancing neutrophil ROS production and fungicidal activity, and JAK&#8211;STAT inhibitors have been reported to promote aspergillosis in humans<sup><xref ref-type="bibr" rid="CR92">92</xref></sup> (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). In addition, STAT1 signalling in CCR2<sup>+</sup> monocytes facilitates the formation of monocyte-derived DCs and enhances their fungicidal activity; this process is supported by reciprocal interferon&#8211;STAT1 crosstalk with neutrophils<sup><xref ref-type="bibr" rid="CR93">93</xref></sup>. Fungus-induced release of GM-CSF also stimulates neutrophil ROS production and promotes fungal clearance<sup><xref ref-type="bibr" rid="CR94">94</xref></sup>. Concordantly, humans with mutations in GM-CSF receptor signalling develop pulmonary alveolar proteinosis, a condition that is associated with opportunistic pulmonary infections, including aspergillosis<sup><xref ref-type="bibr" rid="CR95">95</xref></sup> (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>).</p><p id="Par27">Upon conidial engulfment, lung-infiltrating neutrophils and monocytes produce CXCR3-targeted chemokines (CXCL9 and CXCL10) to recruit circulating CXCR3<sup>+</sup> plasmacytoid DCs into the lung, where they boost neutrophil ROS production, neutrophil extracellular trap formation and fungicidal activity<sup><xref ref-type="bibr" rid="CR84">84</xref></sup>. Thus, both epithelial cell-derived chemokines and haematopoietic cell-derived chemokines coordinate early neutrophil influx to the <italic toggle="yes">Aspergillus</italic>-infected lung, and tissue-infiltrating mononuclear phagocytes license neutrophil functions to achieve sterilizing immunity. Nutrient limitation via metal chelators (for example, lactoferrin or calprotectin) also contributes to tissue-specific control of <italic toggle="yes">Aspergillus</italic>, with a role shown for calprotectin in protecting against <italic toggle="yes">Aspergillus</italic> keratitis but not pulmonary infection in mice<sup><xref ref-type="bibr" rid="CR96">96</xref>,<xref ref-type="bibr" rid="CR97">97</xref></sup>. Corroborating these mechanistic studies of protective immunity in mice, human population studies have identified genetic polymorphisms in <italic toggle="yes">APCS</italic> (encoding pentraxin 2), <italic toggle="yes">PTX3</italic>, <italic toggle="yes">CLEC7A</italic> (encoding dectin&#160;1), <italic toggle="yes">CLEC1A</italic> and <italic toggle="yes">CXCL10</italic> that predispose to aspergillosis following allogeneic HSCT<sup><xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR77">77</xref>,<xref ref-type="bibr" rid="CR98">98</xref>,<xref ref-type="bibr" rid="CR99">99</xref></sup>.</p><p id="Par28">Moreover, pharmacological susceptibility to aspergillosis has provided additional insights into host defence pathways (Table&#160;<xref rid="Tab3" ref-type="table">3</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">3</xref>). Chief among these is the observation that ibrutinib-induced inhibition of Bruton&#8217;s tyrosine kinase (BTK) promotes aspergillosis in patients with lymphoma<sup><xref ref-type="bibr" rid="CR100">100</xref>,<xref ref-type="bibr" rid="CR101">101</xref></sup>, which is recapitulated in <italic toggle="yes">Btk</italic><sup><italic toggle="yes">&#8722;/&#8722;</italic></sup> mice, consistent with BTK having an evolutionarily conserved role in defence against <italic toggle="yes">Aspergillus</italic><sup><xref ref-type="bibr" rid="CR100">100</xref></sup>. In macrophages, phagocytosis of <italic toggle="yes">Aspergillus</italic> conidia triggers dectin&#160;1-dependent and Toll-like receptor&#160;9 (TLR9)-dependent activation of BTK, which regulates calcineurin&#8211;NFAT activity and synergizes with NF-&#954;B to promote the production of tumour necrosis factor (TNF)<sup><xref ref-type="bibr" rid="CR102">102</xref></sup>. The mechanisms by which BTK mediates neutrophil anti-<italic toggle="yes">Aspergillus</italic> defence remain poorly defined and require further study.</p></sec><sec id="Sec7"><title>Mucormycosis</title><p id="Par29">Mucormycosis is a life-threatening infection caused by ubiquitous inhaled moulds of the order Mucorales (primarily <italic toggle="yes">Rhizopus</italic> species)<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>. As is the case for aspergillosis, mucormycosis typically occurs in patients with quantitative and/or qualitative phagocyte defects, such as individuals with neutropenia, who&#160;receive corticosteroids or who are HSCT recipients<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>. However, Mucorales members are unique among the human mould pathogens in terms of their predilection to cause disease in the settings of&#160;<xref rid="Glos12" ref-type="list">diabetic ketoacidosis</xref> or iron overload<sup><xref ref-type="bibr" rid="CR103">103</xref></sup> (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">1</xref>). Moreover, mucormycosis has emerged as a devastating complication of COVID-19, particularly in India (where it had a prevalence of 0.27% among hospitalized patients with COVID-19), associated with corticosteroid use and uncontrolled hyperglycaemia<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Strikingly, mucormycosis has distinct infection patterns in patients with different risk factors. Specifically, diabetic ketoacidosis typically predisposes to the rhino-orbital&#8211;cerebral form of the disease, whereas patients with neutropenia or who are HSCT recipients typically develop sinopulmonary mucormycosis<sup><xref ref-type="bibr" rid="CR103">103</xref></sup>.</p><p id="Par30">During infection in mice, Mucorales members produce mucoricin, a plant ricin-like toxin that promotes cellular necrosis, vascular permeability and death<sup><xref ref-type="bibr" rid="CR104">104</xref></sup>. Recent work has uncovered tissue-specific mechanisms by which hyperglycaemia and iron overload increase susceptibility to mucormycosis. Specifically, increased levels of glucose, iron and ketone bodies, all of which occur during diabetic ketoacidosis, attenuate neutrophil-mediated damage to <italic toggle="yes">Rhizopus</italic> and induce expression of the glucose-regulated receptor GRP78 on the surface of endothelial cells and nasal epithelial cells and of the Mucorales invasin CotH3 (refs. <xref ref-type="bibr" rid="CR105">105</xref>&#8211;<xref ref-type="bibr" rid="CR108">108</xref>). The CotH3&#8211;GRP78 interaction enables fungal invasion and damage of the nasal epithelium, and can be targeted with therapeutic benefit in <italic toggle="yes">Rhizopus</italic>-infected mice with diabetic ketoacidosis<sup><xref ref-type="bibr" rid="CR105">105</xref>&#8211;<xref ref-type="bibr" rid="CR107">107</xref></sup>. Because <italic toggle="yes">Aspergillus</italic> does not encode CotH3, this functional attribute of Mucorales may underlie the selective predisposition of patients with diabetes to mucormycosis. By contrast, in the setting of pulmonary mucormycosis, <italic toggle="yes">Rhizopus</italic> CotH7 interacts with &#946;1&#160;integrin, not GRP78, on the surface of alveolar epithelial cells to promote fungal invasion, EGFR activation and cellular damage<sup><xref ref-type="bibr" rid="CR108">108</xref>,<xref ref-type="bibr" rid="CR109">109</xref></sup>. Pharmacological inhibition of &#946;1&#160;integrin or EGFR with the FDA-approved inhibitors cetuximab or gefitinib blocks fungal invasion of alveolar epithelial cells and prolongs mouse survival during pulmonary mucormycosis<sup><xref ref-type="bibr" rid="CR108">108</xref>,<xref ref-type="bibr" rid="CR109">109</xref></sup>. Thus, <italic toggle="yes">Rhizopus</italic> interacts with different tissue-specific mammalian receptors depending on the underlying predisposing factor to instigate opportunistic disease. Furthermore, during pulmonary mucormycosis in mice, alveolar macrophages contribute to fungal clearance and host survival by stimulating an intracellular iron restriction programme that curbs <italic toggle="yes">Rhizopus</italic> growth within phagosomes, underscoring the importance of protective nutritional immunity in this setting<sup><xref ref-type="bibr" rid="CR110">110</xref></sup>.</p></sec><sec id="Sec8"><title>Chromoblastomycosis and phaeohyphomycosis</title><p id="Par31">Chromoblastomycosis is a disfiguring, tumour-like, progressive and often treatment-unresponsive infection in tropical areas, which has been designated as a neglected tropical disease by the World Health Organization. It is primarily caused by the pigmented fungus <italic toggle="yes">Fonsecaea pedrosoi</italic>, which typically enters the skin via traumatic inoculation (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">1</xref>). In <italic toggle="yes">F. pedrosoi</italic>-infected mice, CD4<sup>+</sup> T cells are essential for fungal clearance, primarily involving T<sub>H</sub>1 cell and T<sub>H</sub>17 cell responses<sup><xref ref-type="bibr" rid="CR111">111</xref>,<xref ref-type="bibr" rid="CR112">112</xref></sup>. Unlike <italic toggle="yes">Candida</italic> and <italic toggle="yes">Aspergillus</italic> species, <italic toggle="yes">F. pedrosoi</italic> stimulates modest CLR responses through the dectin&#160;2-dependent and Mincle-dependent SYK&#8211;CARD9 axis and fails to effectively activate TLRs, resulting in inadequate local inflammatory responses in infected mice and humans<sup><xref ref-type="bibr" rid="CR111">111</xref>,<xref ref-type="bibr" rid="CR113">113</xref></sup>. Topical administration of the TLR7 agonist imiquimod combined with antifungal therapy markedly improved clinical outcomes in patients with refractory chromoblastomycosis<sup><xref ref-type="bibr" rid="CR114">114</xref></sup>, demonstrating a key adjunctive role for this immunotherapeutic intervention.</p><p id="Par32">Phaeohyphomycosis is another mycosis caused by melanin-bearing, pigmented fungi that typically enter the skin via traumatic inoculation. Although infection is self-limited in most healthy individuals, it can cause severe subcutaneous or disseminated disease in patients who are HSCT recipients or who have CARD9 deficiency<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR115">115</xref></sup> (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">1</xref>). <italic toggle="yes">Exserohilum rostratum</italic>, one of the agents of phaeohyphomycosis, caused a meningitis outbreak following epidural injections of contaminated methylprednisolone in the USA in 2012 (ref. <xref ref-type="bibr" rid="CR116">116</xref>). CARD9-dependent defence against phaeohyphomycosis in mice was recently shown to rely on macrophages, whereas neutrophil recruitment to the infected skin was CARD9 independent<sup><xref ref-type="bibr" rid="CR117">117</xref></sup>. Specifically, CARD9 primes macrophages to produce IL-1&#946; and TNF, which promote macrophage killing of fungi in an interdependent manner<sup><xref ref-type="bibr" rid="CR117">117</xref></sup>. Consistent with this finding, phaeohyphomycosis has been reported following treatment with TNF-targeted biologics such as infliximab<sup><xref ref-type="bibr" rid="CR118">118</xref></sup> (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Upstream of CARD9, dectin&#160;1 is also crucial for macrophage-mediated defence against phaeohyphomycosis in mice, and deleterious mutations in the gene encoding dectin&#160;1 (<italic toggle="yes">CLEC7A</italic>) that impair fungal sensing and TNF production were found in ~70% of putatively immunocompetent patients with severe forms of phaeohyphomycosis<sup><xref ref-type="bibr" rid="CR117">117</xref></sup>. These findings suggest that human dectin&#160;1 deficiency may contribute to susceptibility to severe phaeohyphomycosis in the setting of traumatic inoculation.</p></sec><sec id="Sec9"><title>Cryptococcosis</title><p id="Par33">Cryptococcosis is caused by the encapsulated yeasts <italic toggle="yes">Cryptococcus neoformans</italic> and <italic toggle="yes">Cryptococcus gattii</italic>, which have distinct infection patterns in humans<sup><xref ref-type="bibr" rid="CR119">119</xref></sup>. <italic toggle="yes">C. neoformans</italic> is more common, and typically causes meningoencephalitis in immunocompromised patients with CD4<sup>+</sup> T cell depletion and/or dysfunction (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Cryptococcal meningoencephalitis is an AIDS-defining illness and remains a significant cause of death in resource-limited areas (for example, some parts of Africa) that are associated with limited availability of antiretroviral therapy and first-line antifungal drugs. The incidence of cryptococcal meningoencephalitis is increasing in non-HIV-infected individuals in the Western hemisphere. By contrast, <italic toggle="yes">C. gattii</italic> primarily causes pulmonary disease in putatively immunocompetent individuals and rarely affects individuals with HIV/AIDS.</p><p id="Par34">Human exposure to inhaled <italic toggle="yes">Cryptococcus</italic> is widespread by early childhood. The crucial immunological checkpoint for preventing local proliferation of yeast in the lung and extrapulmonary dissemination is the containment and killing of inhaled <italic toggle="yes">Cryptococcus</italic> by lung-resident macrophages, which is enabled by their crosstalk with IFN&#947;-producing CD4<sup>+</sup> T cells<sup><xref ref-type="bibr" rid="CR119">119</xref></sup> (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Notably, <italic toggle="yes">Cryptococcus</italic> yeasts secrete a capsule containing glucuronoxylomannan and galactoxylomannan that shields its pathogen-associated molecular patterns from immune recognition<sup><xref ref-type="bibr" rid="CR119">119</xref>,<xref ref-type="bibr" rid="CR120">120</xref></sup>. Unsurprisingly, therefore, defective TLR-mediated and CLR-mediated responses in the setting of human MYD88 deficiency and CARD9 deficiency, respectively, do not predispose to cryptococcosis<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. By contrast, a few inborn errors of immunity primarily affecting numbers of lymphocytes and/or monocytes and macrophages, and/or their activation, underlie human cryptococcosis (Table&#160;<xref rid="Tab2" ref-type="table">2</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>), which supports the crucial role of effective crosstalk between lymphocytes and mononuclear phagocytes in cryptococcal clearance<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR119">119</xref></sup>.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><title>Crosstalk between macrophages and T cells during infection with intracellular fungi.</title><p>Type 1 immune responses, characterized by interferon-&#947; (IFN&#947;)-producing T cells and macrophages, are crucial for protection against intramacrophagic fungi (such as <italic toggle="yes">Cryptococcus</italic> and <italic toggle="yes">Histoplasma</italic>). Infected macrophages produce IL-12, which drives T helper 1 (T<sub>H</sub>1) cell polarization of CD4<sup>+</sup> T cells through Janus kinase&#160;2 (JAK2)&#8211;signal transducer and activator of transcription&#160;4 (STAT4) signalling. T<sub>H</sub>1 cells produce IFN&#947;, which binds to the IFN&#947; receptor, comprising IFNGR1 and IFNGR2, on macrophages and activates JAK1/JAK2&#8211;STAT1-dependent signalling to induce expression of inducible nitric oxide synthase (iNOS). In turn, iNOS mediates fungal killing together with the production of reactive oxygen species (ROS), which is partly controlled by sphingosine 1-phosphate receptor&#160;3 (S1PR3) in the setting of cryptococcal infection. Tumour necrosis factor (TNF) activates macrophages for fungal killing and promotes the formation of granulomas and IFN&#947; production by lymphocytes. Granulocyte&#8211;macrophage colony-stimulating factor (GM-CSF) also primes macrophages to effectively kill fungi intracellularly. The transcription factor GATA2 regulates fungal uptake by macrophages<sup><xref ref-type="bibr" rid="CR184">184</xref></sup>. Disruption of these protective antifungal immune pathways by biologics, inborn errors of immunity or anti-cytokine autoantibodies enhances susceptibility to infections with intracellular fungi in humans.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e2788" position="float" orientation="portrait" xlink:href="41577_2022_826_Fig3_HTML.jpg"/></fig></p><p id="Par35">Loss-of-function mutations in <italic toggle="yes">IL12RB1</italic> are associated with cryptococcosis, which is explained by impaired IL-12-driven IFN&#947; production by T cells and the resulting inability of macrophages to promote intracellular killing of fungi<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). Consistent with this notion, cryptococcosis develops in adult patients with neutralizing autoantibodies to IFN&#947;<sup><xref ref-type="bibr" rid="CR121">121</xref></sup>, which may be amenable to anti-CD20 or anti-CD38 targeted biologics that deplete B cells and plasma cells, respectively<sup><xref ref-type="bibr" rid="CR122">122</xref>,<xref ref-type="bibr" rid="CR123">123</xref></sup>. The higher prevalence of autoantibodies to IFN&#947; in individuals of Asian ancestry who were born in Asia but not elsewhere suggests that both environmental and genetic factors are involved<sup><xref ref-type="bibr" rid="CR121">121</xref></sup>. Moreover, impaired T cell responses promote cryptococcosis in the setting of CD40L deficiency<sup><xref ref-type="bibr" rid="CR124">124</xref></sup>. GATA2 deficiency predisposes to infection with various intramacrophagic pathogens, including mycobacteria and <italic toggle="yes">Cryptococcus</italic>, associated with profound monocytopenia<sup><xref ref-type="bibr" rid="CR125">125</xref></sup>. GM-CSF is a key factor that promotes anticryptococcal immunity by activating macrophages to a functional state that is associated with efficient fungal killing<sup><xref ref-type="bibr" rid="CR126">126</xref></sup>. Inherited deficiency of GM-CSF receptor signalling or neutralizing autoantibodies to GM-CSF can underlie cryptococcosis, with an enrichment for <italic toggle="yes">C. gattii</italic> infections in particular<sup><xref ref-type="bibr" rid="CR121">121</xref>,<xref ref-type="bibr" rid="CR127">127</xref></sup>. A genome-wide association study in individuals with HIV/AIDS of African descent uncovered a correlation between <italic toggle="yes">CSF1</italic> genetic variation and cryptococcosis<sup><xref ref-type="bibr" rid="CR128">128</xref></sup>. <italic toggle="yes">CSF1</italic> encodes macrophage colony-stimulating factor (M-CSF), another growth factor that is crucial for macrophage activation and survival, particularly for CNS-resident microglia<sup><xref ref-type="bibr" rid="CR129">129</xref></sup>.</p><p id="Par36">Pharmacological susceptibility to cryptococcosis has provided additional evidence for the importance of crosstalk between T<sub>H</sub>1 cells and macrophages (Table&#160;<xref rid="Tab3" ref-type="table">3</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">3</xref>). For example, JAK&#8211;STAT inhibitors (which block IFN&#947; receptor signalling), TNF inhibitors (which impair IFN&#947; production and granuloma formation) and BTK inhibitors (which impair macrophage activation) all increase the risk of cryptococcosis<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. Alemtuzumab (which targets CD52 on lymphocytes) and natalizumab (which targets &#945;4&#946;1 integrin on lymphocytes) promote cryptococcosis through profound and prolonged T cell depletion and through impaired integrin-mediated T cell trafficking to <italic toggle="yes">Cryptococcus</italic>-infected tissues, respectively<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. The sphingosine 1-phosphate receptor (S1PR) inhibitor fingolimod was recently reported to promote cryptococcosis. In a mouse model of cryptococcosis, fingolimod enhanced susceptibility by impairing S1PR3-dependent macrophage phagocytosis and granuloma formation and by driving a macrophage phenotype with poor oxidative killing capacity, not by affecting S1PR1-mediated T cell trafficking<sup><xref ref-type="bibr" rid="CR130">130</xref></sup>.</p><p id="Par37">Defective IFN&#947; signalling in macrophages impairs the activity of inducible nitric oxide synthase (iNOS) and hence macrophage oxidative killing pathways, which enables <italic toggle="yes">Cryptococcus</italic> to survive within phagosomes, where it can be shielded from immune recognition, as has been shown in infected brain tissue of patients with HIV/AIDS<sup><xref ref-type="bibr" rid="CR131">131</xref></sup>. Intracellular growth in macrophages is promoted by fungal-derived urease and modification of the phagosome microenvironment<sup><xref ref-type="bibr" rid="CR132">132</xref>,<xref ref-type="bibr" rid="CR133">133</xref></sup>. In patients with HIV/AIDS, a lack of CD4<sup>+</sup> T cells and paucity of pro-inflammatory cytokines (IFN&#947; and TNF) in the cerebrospinal fluid were the strongest predictors of cryptococcosis severity in the CNS, and T cell responses producing IFN&#947; and TNF were associated with increased survival<sup><xref ref-type="bibr" rid="CR134">134</xref>&#8211;<xref ref-type="bibr" rid="CR136">136</xref></sup>. Consistent with the idea that IFN&#947; may boost macrophage antifungal activity in patients with HIV/AIDS in the absence of T cell help, a clinical trial showed that adjunctive IFN&#947; immunotherapy rapidly reduced fungal burden in the cerebrospinal fluid, the level of which is a known surrogate of patient survival<sup><xref ref-type="bibr" rid="CR137">137</xref></sup>.</p><p id="Par38">Although they are crucial for fungal control, T<sub>H</sub>1 cells may also promote pathogenic effects in the settings of non-HIV cryptococcosis and HIV-associated immune reconstitution inflammatory syndrome (IRIS), a condition characterized by the development of life-threatening immunopathology upon initiation of antiretroviral therapy. In these patients, corticosteroids ameliorate inflammatory sequelae and neurological symptoms<sup><xref ref-type="bibr" rid="CR138">138</xref></sup>. In patients without HIV infection with cryptococcosis, significant infiltration of CXCR3<sup>+</sup> T<sub>H</sub>1 cells into the CNS is observed, associated with high levels of CXCL10 in cerebrospinal fluid, poor colocalization of macrophages and fungus, and neuronal damage<sup><xref ref-type="bibr" rid="CR139">139</xref></sup>. Correspondingly, in a mouse model of non-HIV cryptococcosis, CXCR3 inhibition abrogated the recruitment of T<sub>H</sub>1 cells into the CNS by glial-derived CXCL10 and increased survival<sup><xref ref-type="bibr" rid="CR140">140</xref></sup>. Furthermore, patients with AIDS&#160;without&#160;IRIS have increased numbers of T<sub>H</sub>1 cells and increased serum levels of IFN&#947; relative to patients without IRIS<sup><xref ref-type="bibr" rid="CR141">141</xref></sup>. In a mouse model of cryptococcus-associated IRIS, IFN&#947;-producing CD4<sup>+</sup> T cells were sufficient to mediate CNS damage associated with upregulation of aquaporin&#160;4, which modulates water influx and swelling within the brain<sup><xref ref-type="bibr" rid="CR142">142</xref></sup>. Better understanding of the molecular underpinnings of pathogenic inflammation during cryptococcus-associated IRIS may help to identify targeted, corticosteroid-sparing immunomodulatory strategies for affected patients.</p></sec><sec id="Sec10"><title>Other endemic fungal infections</title><p id="Par39"><italic toggle="yes">Histoplasma</italic>, <italic toggle="yes">Coccidioides</italic>, <italic toggle="yes">Paracoccidioides, Talaromyces</italic> and <italic toggle="yes">Blastomyces</italic> species are geographically restricted dimorphic fungi that typically cause self-limited pneumonia in healthy individuals but that can lead to progressive pulmonary and/or extrapulmonary disease in immunocompromised patients with HIV/AIDS, corticosteroid use or transplantation (Table&#160;<xref rid="Tab1" ref-type="table">1</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">1</xref>). Race, ethnicity and hormonal factors can influence the risk and severity of these infections, through mechanisms that remain poorly understood. For example, African American, Native American and Asian ancestries are associated with increased risk of blastomycosis and disseminated coccidioidomycosis, pregnancy increases the risk of severe coccidioidomycosis, and chronic paracoccidioidomycosis more commonly affects males<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>.</p><p id="Par40">As for cryptococcosis, defence against histoplasmosis, coccidioidomycosis, paracoccidioidomycosis, talaromycosis and blastomycosis depends on the coordinated crosstalk between IFN&#947;-producing T cells and fungicidal macrophages (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>). In line with this crucial role of granulomatous inflammation, inborn errors of immunity affecting type&#160;1 immune responses caused by mutations in the genes encoding IL-12RB1, IFN&#947;R1, STAT1, STAT3, CD40L or GATA2 (Table&#160;<xref rid="Tab2" ref-type="table">2</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>) predispose to severe, disseminated infections by these fungi, as do neutralizing autoantibodies to IFN&#947;<sup><xref ref-type="bibr" rid="CR121">121</xref></sup> and receipt of TNF inhibitors, JAK&#8211;STAT inhibitors or the IFN&#947;-targeted biologic emapalumab<sup><xref ref-type="bibr" rid="CR9">9</xref></sup> (Table&#160;<xref rid="Tab3" ref-type="table">3</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">3</xref>). In <italic toggle="yes">Coccidioides</italic>-infected patients, genetic variants in &#946;-glucan sensing and response genes (for example, <italic toggle="yes">CLEC7A</italic> and <italic toggle="yes">PLCG2</italic>) that impair TNF production were recently shown to underlie disseminated disease in ~50% of evaluated patients<sup><xref ref-type="bibr" rid="CR143">143</xref></sup>. By contrast, type&#160;2 immune responses are detrimental for pathogen control by dampening type&#160;1 responses and skewing macrophages towards a phenotype that is permissive for intracellular fungal persistence<sup><xref ref-type="bibr" rid="CR144">144</xref></sup>. Macrophage-mediated nutritional immunity to <italic toggle="yes">Histoplasma</italic> is also mediated by T<sub>H</sub>1 cell responses, particularly GM-CSF, which promotes metallothionein-mediated zinc sequestration that starves the pathogen. By contrast, the T<sub>H</sub>2 cell cytokine IL-4 promotes zinc acquisition by yeast, which enables its intracellular survival<sup><xref ref-type="bibr" rid="CR145">145</xref></sup>. The <italic toggle="yes">Blastomyces</italic> adhesin BAD1 inhibits CD4<sup>+</sup> T cell-derived IFN&#947; release, and <italic toggle="yes">Blastomyces</italic> uses additional immune-evasion strategies, including cleavage and inactivation of GM-CSF and of monocyte-recruiting CC&#160;chemokines<sup><xref ref-type="bibr" rid="CR146">146</xref></sup>.</p><p id="Par41">Immunomodulatory restoration of the T<sub>H</sub>1 cell&#8211;T<sub>H</sub>2 cell balance during endemic mycoses can be exploited with therapeutic benefit. Specifically, a child with no known inborn error of immunity and refractory disseminated coccidioidomycosis who had increased levels of IL-4 and decreased levels of IFN&#947; achieved rapid symptom resolution and infection remission after adjunctive administration of recombinant IFN&#947; and the IL-4/IL-13 receptor inhibitor dupilumab<sup><xref ref-type="bibr" rid="CR147">147</xref></sup>.</p></sec><sec id="Sec11"><title><italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia</title><p id="Par42"><italic toggle="yes">Pneumocystis jirovecii</italic> pneumonia (PJP) is an AIDS-defining illness that develops with declining CD4<sup>+</sup> T cell counts and carries a high global disease burden and mortality. In HIV-negative individuals, PJP is most often seen following corticosteroid administration (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Epidemiological data indicate that inhalational exposure to <italic toggle="yes">P. jirovecii</italic> is universal during infancy without causing severe clinical disease, which is indicative of potent, protective host responses to <italic toggle="yes">Pneumocystis</italic><sup><xref ref-type="bibr" rid="CR148">148</xref></sup>. In mice infected with <italic toggle="yes">Pneumocystis murina</italic>, the mouse-specific <italic toggle="yes">Pneumocystis</italic> species, CD4<sup>+</sup> T cells are crucial for defence as CD4-deficient animals are highly susceptible, which is consistent with the increased risk of PJP in individuals with HIV/AIDS or patients treated with the T cell-depleting biologic alemtuzumab (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Although T<sub>H</sub>1 cells, T<sub>H</sub>2 cells and T<sub>H</sub>17 cells are all induced during mouse infection, none of them has been shown individually to promote disease resolution using corresponding gene-deficient mouse strains<sup><xref ref-type="bibr" rid="CR149">149</xref></sup>. Recently, CD4<sup>+</sup> T cell-intrinsic signalling through IL-21R and STAT3 was found to be crucial for defence in <italic toggle="yes">Pneumocystis</italic>-infected mice, by priming T cell effector functions and protective class-switched antibody responses<sup><xref ref-type="bibr" rid="CR150">150</xref></sup>. These findings recapitulate the susceptibility to PJP that is seen in patients with <italic toggle="yes">STAT3</italic> and <italic toggle="yes">IL21R</italic> mutations (Table&#160;<xref rid="Tab2" ref-type="table">2</xref> and Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>). In&#160;addition to T cells, B cells are also crucial for anti-<italic toggle="yes">Pneumocystis</italic> defence through antigen presentation to and priming of CD4<sup>+</sup> T cell responses in the lung, by facilitating opsonic phagocytosis by alveolar macrophages, and through secreted IgM<sup><xref ref-type="bibr" rid="CR151">151</xref>&#8211;<xref ref-type="bibr" rid="CR153">153</xref></sup>. In agreement with this role for B cells, recipients of CD20-targeted B cell-depleting antibodies are at risk of developing PJP (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">3</xref>). Among myeloid phagocytes, alveolar macrophages and eosinophils, but not neutrophils, contribute to <italic toggle="yes">Pneumocystis</italic> clearance during mouse infection<sup><xref ref-type="bibr" rid="CR154">154</xref>,<xref ref-type="bibr" rid="CR155">155</xref></sup>. Other PJP-manifesting inborn errors of immunity that involve impaired T cell and/or B cell responses include severe combined immunodeficiency, anhidrotic ectodermal dysplasia with immune deficiency due to IKBA deficiency, and mutations in <italic toggle="yes">CD40L</italic>, <italic toggle="yes">IKZF1</italic> or <italic toggle="yes">IKZF3</italic> (ref. <xref ref-type="bibr" rid="CR149">149</xref>) (Supplementary Table&#160;<xref rid="MOESM1" ref-type="media">2</xref>). Biologics that predispose humans to PJP include TNF, PI3K and JAK&#8211;STAT inhibitors, which impair the responses of T cells and macrophages to <italic toggle="yes">Pneumocystis</italic><sup><xref ref-type="bibr" rid="CR149">149</xref></sup> (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec12"><title>Endogenous fungi: protection and pathology</title><p id="Par43">Fungi are core constituents of endogenous microbial communities at several human barrier sites (Box&#160;<xref rid="Sec13" ref-type="sec">3</xref>). Recent studies have advanced the concept that tissue-resident fungi shape immune homeostasis and development, function as reservoirs for invasive fungal infections and contribute to the pathogenesis of autoimmune, inflammatory and neoplastic diseases (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>). Here we focus primarily on human studies of the mycobiota, with mouse work having been reviewed elsewhere<sup><xref ref-type="bibr" rid="CR156">156</xref>,<xref ref-type="bibr" rid="CR157">157</xref></sup>.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><title>Endogenous fungal communities and their relationship to invasive fungal disease.</title><p><bold>a</bold>, Mucosal and intestinal bacterial communities outnumber and compete with site-specific endogenous fungi. In the intestine, commensal anaerobic bacteria, exemplified by <italic toggle="yes">Blautia producta</italic> and <italic toggle="yes">Bacteroides thetaiotaomicron</italic>, provide colonization resistance against <italic toggle="yes">Candida</italic> species by activating the transcription factor hypoxia-inducible factor 1&#945; (HIF1&#945;) in intestinal epithelial cells to regulate the release of LL-37, an antimicrobial peptide (AMP) that restricts <italic toggle="yes">Candida albicans</italic> growth. Bacterial products of fermentation, specifically short-chain fatty acids (SCFAs), and metabolites likely also contribute to fungal colonization resistance and inhibition of <italic toggle="yes">Candida</italic> filamentation. Nutrient competition and regulation of tissue oxygen levels contribute to the balance between endogenous bacteria and competing fungal species in the gastrointestinal and reproductive tracts. CX3CR1<sup>+</sup> mononuclear phagocytes recognize intestinal fungi through C-type lectin receptor (CLR)&#8211;CARD9 signalling and regulate the production of IgA and IgG antibodies to <italic toggle="yes">Candida</italic> by B cells. IgA antibodies recognize and target <italic toggle="yes">C. albicans</italic> adhesins (such as agglutinin-like sequence&#160;3 (Als3)) that are primarily expressed by pseudohyphae and thus promote maintenance of the commensal yeast cell morphology. <italic toggle="yes">Candida</italic>-targeted IgG antibodies can protect against bloodstream invasion and disseminated candidiasis. <bold>b</bold>, In the intestinal and reproductive tracts, antibiotic-induced loss of predominantly anaerobic bacterial taxa reduces <italic toggle="yes">Candida</italic> colonization resistance and facilitates domination by individual fungal taxa. <italic toggle="yes">C. albicans</italic> strains from patients with inflammatory bowel disease with fungal dysbiosis can aggravate tissue damage, correlating with fungal strain-specific induction of IL-1&#946; production by immune cells. The induction of T helper 17 (T<sub>H</sub>17) cells and IL-17 production can promote neutrophil recruitment to inhibit fungal tissue invasion and dissemination. However, <italic toggle="yes">Candida</italic>-specific T<sub>H</sub>17 cells can also promote extraintestinal inflammation. For example, mould aeroallergens can stimulate <italic toggle="yes">C. albicans</italic>-primed T<sub>H</sub>17 cells and aggravate fungus-associated asthma. <bold>c</bold>, Systemic bloodstream infections can arise from intestinal fungal dysbiosis with concomitant epithelial cell damage (for example, following chemotherapy) and with defects in the number or function of circulating myeloid phagocytes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e3279" position="float" orientation="portrait" xlink:href="41577_2022_826_Fig4_HTML.jpg"/></fig></p><p id="Par44">In early human life, fungal&#8211;bacterial interactions shape the orderly assembly of the microbiota<sup><xref ref-type="bibr" rid="CR158">158</xref></sup>. For example, ecological modelling in preterm neonates in an intensive care unit predicted that high abundance of intestinal <italic toggle="yes">Candida</italic> inhibited the expansion of Enterobacteriaceae, which facilitate the ensuing transition to commensal bacterial anaerobes<sup><xref ref-type="bibr" rid="CR159">159</xref></sup>. This prediction was validated in interkingdom co-culture experiments with infant-derived <italic toggle="yes">Candida</italic> strains and in sequential intestinal colonization studies in mice, which showed that gut-resident <italic toggle="yes">Candida</italic> decreased the load of sequentially introduced Enterobacteriaceae. A recent review provides an excellent summary of numerous studies on the functional interactions between commensal, probiotic and potentially pathogenic bacteria and fungi<sup><xref ref-type="bibr" rid="CR160">160</xref></sup>.</p><p id="Par45">In addition to the role of fungi in microbiota assembly, the density of intestinal fungi and, in particular, the abundance of <italic toggle="yes">Pichia kudriavzevii</italic> (the sexual state of <italic toggle="yes">Candida krusei</italic>) have been linked to subsequent atopy in independent birth cohorts<sup><xref ref-type="bibr" rid="CR161">161</xref></sup>. Transient <italic toggle="yes">P. kudriavzevii</italic> colonization exacerbated house dust mite-induced allergic airway disease in neonatal specific pathogen-free mice<sup><xref ref-type="bibr" rid="CR161">161</xref></sup>. In human adults, circulating fungus-reactive memory T<sub>H</sub>17 cells preferentially target <italic toggle="yes">C. albicans</italic>-derived antigens, consistent with the idea that intestinal colonization with <italic toggle="yes">C. albicans</italic> induces T<sub>H</sub>17 cell differentiation<sup><xref ref-type="bibr" rid="CR162">162</xref></sup>. Circulating <italic toggle="yes">C. albicans</italic>-induced T<sub>H</sub>17 cells cross-react with other fungi and can exacerbate the pathology of <italic toggle="yes">A. fumigatus</italic>-triggered allergic lung disease.</p><p id="Par46"><italic toggle="yes">Malassezia</italic>, the major fungal commensal of human skin<sup><xref ref-type="bibr" rid="CR163">163</xref></sup>, can cause pityriasis versicolor, characterized by hyperpigmented or hypopigmented flaky skin lesions. In a mouse epicutaneous infection model, <italic toggle="yes">Malassezia</italic> induced T<sub>H</sub>17 cell differentiation and elicited IL-23-dependent IL-17 release by &#947;&#948; T cells and type&#160;3 innate lymphoid cells<sup><xref ref-type="bibr" rid="CR164">164</xref></sup>. These sources of IL-17 restrict fungal growth in intact skin but can exacerbate <italic toggle="yes">Malassezia</italic>-driven inflammation in injured skin. Local IL-17 recall responses to <italic toggle="yes">Malassezia</italic> and <italic toggle="yes">Candida</italic> also aggravated psoriasiform skin inflammation in mice, which recapitulates transcriptional features of human psoriatic skin lesions<sup><xref ref-type="bibr" rid="CR165">165</xref></sup>.</p><p id="Par47">In the gut, the humoral immune response can shape mutualism between intestinal <italic toggle="yes">Candida</italic> and its human host by preferentially targeting adhesins expressed by <italic toggle="yes">C. albicans</italic> hyphae but not the yeast form. This IgA-dependent selection favours the growth of yeast rather than hyphal morphotypes in the intestine and enhances the competitive fitness of yeast in antibiotic-treated mice<sup><xref ref-type="bibr" rid="CR166">166</xref>,<xref ref-type="bibr" rid="CR167">167</xref></sup>. Furthermore, the human repertoire of antibodies to <italic toggle="yes">C. albicans</italic> includes IgG antibodies, which depend on CARD9<sup>+</sup> intestinal macrophages to promote their production and are protective in mice infected systemically with <italic toggle="yes">C. albicans</italic> and <italic toggle="yes">C. auris</italic><sup><xref ref-type="bibr" rid="CR168">168</xref></sup>.</p><p id="Par48">Commensal anaerobic bacteria can regulate intestinal fungal density, partly by inducing the production of antimicrobial peptides, by producing short-chain fatty acids through fermenting dietary fibre and by maintaining a low-oxygen environment. <italic toggle="yes">Bacteroides</italic> and <italic toggle="yes">Blautia</italic> bacteria activate intestinal epithelial cell signalling through HIF1&#945;, which regulates enterocyte release of the antimicrobial peptide LL-37 and <italic toggle="yes">C. albicans</italic> colonization resistance<sup><xref ref-type="bibr" rid="CR43">43</xref></sup> (Fig.&#160;<xref rid="Fig4" ref-type="fig">4a</xref>). Antibiotics that promote the loss of anaerobic bacterial taxa drive intestinal fungal expansion. For example, antibiotic-induced injury to the bacterial microbiota facilitates intestinal expansion and domination by pathogenic <italic toggle="yes">Candida</italic> (Fig.&#160;<xref rid="Fig4" ref-type="fig">4b</xref>), which in the context of chemotherapy-induced mucosal injury can translocate across the intestinal barrier to cause life-threatening bloodstream infections in HSCT recipients<sup><xref ref-type="bibr" rid="CR169">169</xref></sup> (Fig.&#160;<xref rid="Fig4" ref-type="fig">4c</xref>). Intestinal fungal dysbiosis during the peri-HSCT period is also linked to reduced long-term survival and increased non-relapse mortality<sup><xref ref-type="bibr" rid="CR170">170</xref>,<xref ref-type="bibr" rid="CR171">171</xref></sup>.</p><p id="Par49">In human cohorts, fungal gut dysbiosis characterized by <italic toggle="yes">Malassezia</italic>, <italic toggle="yes">Debaromyces</italic> or <italic toggle="yes">Candida</italic> expansion is associated with inflammatory bowel disease (IBD) phenotypes. In mice, during intestinal wound healing and dextran sodium sulfate (DSS)-induced colitis, the introduction of representative clinical strains from individual fungal genera (<italic toggle="yes">Malassezia</italic>, <italic toggle="yes">Debaromyces</italic> or <italic toggle="yes">Candida</italic>) caused exuberant tissue pathology, whereas laboratory-passaged strains did not<sup><xref ref-type="bibr" rid="CR172">172</xref>&#8211;<xref ref-type="bibr" rid="CR175">175</xref></sup>. Genetic variation in <italic toggle="yes">CLEC7A</italic> (Y238*) and <italic toggle="yes">CARD9</italic> (S12N) is associated with increased risk and severity of IBD<sup><xref ref-type="bibr" rid="CR157">157</xref>,<xref ref-type="bibr" rid="CR176">176</xref>,<xref ref-type="bibr" rid="CR177">177</xref></sup>. Responsiveness to faecal microbiota transplantation in patients with IBD is associated with high levels of <italic toggle="yes">Candida</italic> before faecal microbiota transplantation, and disease amelioration is associated with low levels of <italic toggle="yes">Candida</italic> after faecal microbiota transplantation, which is consistent with the idea that faecal microbiota transplantation may reduce the contribution of fungus-associated inflammation to IBD severity<sup><xref ref-type="bibr" rid="CR178">178</xref></sup>.</p><p id="Par50">A recent study explored how fungal strain-specific attributes affect functional interactions with host cells to affect IBD severity. A collection of <italic toggle="yes">C. albicans</italic> strains cultured from colonic lavages of patients with IBD and non-disease controls was classified on the basis of filamentation properties and ability to induce IL-1&#946; production by macrophages as a measure of strain-dependent aggravation of intestinal inflammation<sup><xref ref-type="bibr" rid="CR179">179</xref></sup> (Fig.&#160;<xref rid="Fig4" ref-type="fig">4b</xref>). High damage-inducing strains induced IL-1&#946;-dependent tissue damage and instructed T<sub>H</sub>17 cell differentiation through recognition of candidalysin. These strain attributes were linked to IBD severity in humans and were recapitulated in a mouse DSS-induced colitis model, in which IL-1 blockade ameliorated inflammation.</p><p id="Par51">In the pancreas, tissue-resident fungi (particularly <italic toggle="yes">Malassezia</italic>) are markedly enriched in pancreatic ductal adenocarcinoma compared with non-cancerous tissue<sup><xref ref-type="bibr" rid="CR180">180</xref></sup>. In a mouse model of pancreatic ductal adenocarcinoma, antifungal drugs ameliorated tumour progression and the reintroduction of <italic toggle="yes">Malassezia</italic> accelerated tumour growth. Mechanistically, mannose-binding lectin bound to <italic toggle="yes">Malassezia</italic> glycans and activated the C3 complement cascade, which enhanced the growth of tumour cells expressing C3a receptor<sup><xref ref-type="bibr" rid="CR180">180</xref></sup>. Depletion of commensal fungi was recently shown to enhance responsiveness to radiotherapy in a mouse model of breast cancer, and intratumoural dectin&#160;1 expression negatively correlated with survival of patients with breast cancer<sup><xref ref-type="bibr" rid="CR181">181</xref></sup>. The recent comprehensive characterization of the composition of the tumour-associated mycobiota across multiple human cancers has revealed the low-level, yet ubiquitous, presence of fungal DNA and cells in a tumour type-specific manner, often in close spatial association with macrophages and malignant cells<sup><xref ref-type="bibr" rid="CR182">182</xref>,<xref ref-type="bibr" rid="CR183">183</xref></sup>. Clinically, certain plasma or tumour-associated mycobiota subtypes were associated with differential response to immunotherapy, disease severity and/or survival, which indicates that cell-free or tumour-associated fungal DNA may be a potentially promising diagnostic and prognostic biomarker in patients with cancer<sup><xref ref-type="bibr" rid="CR182">182</xref>,<xref ref-type="bibr" rid="CR183">183</xref></sup>.</p><sec id="Sec13"><boxed-text position="float" orientation="portrait"><label>Box 3 The human mycobiota: localization, species and biomass</label><p id="Par52">Fungi are core constituents of microbial communities in human tissues, including the skin, mouth and respiratory, intestinal and genitourinary tracts<sup><xref ref-type="bibr" rid="CR160">160</xref></sup>, although they typically account for less than 1% of total microbial amplicon sequences, with 50&#8211;100 fungal genera being reliably identified<sup><xref ref-type="bibr" rid="CR202">202</xref></sup>. A core fungal signature at different tissue sites has been challenging to define, as humans inhale and ingest fungi daily, blurring the distinction between passenger and colonizer species. Longitudinally collected faecal samples show high intra-individual and interindividual variability of fungal taxa, and low day-to-day stability of intestinal fungi, which is in contrast to the relative intra-individual stability of bacterial communities<sup><xref ref-type="bibr" rid="CR170">170</xref>,<xref ref-type="bibr" rid="CR203">203</xref></sup>. Frequent tooth brushing reduced <italic toggle="yes">Candida</italic> levels in dental plaque, saliva and stool, which is consistent with the oral reservoir contributing to intestinal flux<sup><xref ref-type="bibr" rid="CR204">204</xref></sup>. <italic toggle="yes">Saccharomyces</italic> stool levels dropped precipitously when human volunteers consumed <italic toggle="yes">Saccharomyces</italic>-free diets, only to increase again when the volunteers ate a single bite of bread<sup><xref ref-type="bibr" rid="CR204">204</xref></sup>. Notwithstanding this variability, certain genera predominate at distinct sites: <italic toggle="yes">Saccharomyces</italic>, <italic toggle="yes">Candida</italic>, <italic toggle="yes">Debaromyces</italic> and <italic toggle="yes">Pichia</italic> are commonly found in the digestive and genital tracts, <italic toggle="yes">Malassezia</italic> is commonly found in the skin, and <italic toggle="yes">Aspergillus</italic>, <italic toggle="yes">Fusarium</italic>, <italic toggle="yes">Alternaria</italic> and <italic toggle="yes">Cladosporium</italic> moulds are commonly found in the airways, albeit at lower densities. The figure depicts commensal fungal communities that are adapted to specific tissue niches of humans. Common taxa found under homeostatic conditions are indicated, as are common diseases associated with some of these taxa, such as invasive candidiasis, vulvovaginal candidiasis (VVC) and pityriasis versicolor.</p><p id="Par53">Nucleic acid-based methods underestimate fungal biomass given the size difference of bacteria (~0.5&#8211;2-&#956;m diameter) and fungi (~3&#8211;5-&#956;m diameter for yeasts and ~10&#160;to &gt;100&#8201;&#956;m and greater diameter for hyphae) and metagenomic sequencing has not been widely applied to analyse fungal communities, owing to large and complex fungal genomes (typically more than 20 Mb in size, with both haploid and diploid genomes), low fungal reads compared with bacteria and incomplete, poorly annotated reference libraries<sup><xref ref-type="bibr" rid="CR202">202</xref></sup>. Thus, the true size and composition of the mycobiome in humans remain incompletely understood.<graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="d32e3634" orientation="portrait" xlink:href="41577_2022_826_Figa_HTML.jpg"/></p></boxed-text></sec></sec><sec id="Sec14"><title>Conclusions and future perspectives</title><p id="Par54">Opportunistic fungal infections cause a substantial disease burden globally and are a major threat to the well-being of vulnerable patients. The past decade of research on fungal immunology has moved at a remarkable pace and has yielded exciting advances in our basic understanding of the cellular and molecular determinants of antifungal defences. In this Review, we have delineated promising immunogenomic factors that may enable personalized risk assessment and prognosis of patients at risk of fungal disease, and adjunctive immunotherapeutic strategies that may protect fungus-infected patients by modulating antifungal responses. We have highlighted the expanding universe of inherited and iatrogenic immunodeficiency conditions that predispose to opportunistic fungal disease, as well as the conceptual advances in our understanding of protective and pathogenic antifungal immune pathways that have been derived from studying these conditions. We have also discussed how the endogenous mycobiota shape immune homeostasis and regulate responses to neoplasia, infections, autoimmunity and other exogenous insults. Moving forward, further increasing our understanding of tissue-specific mechanisms of antifungal defence should help to improve the management of life-threatening fungal infections and curtail their detrimental impact on human health.</p></sec><sec sec-type="supplementary-material"><title>Supplementary information</title><sec id="Sec15"><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41577_2022_826_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary information</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41577-022-00826-w.</p></sec><ack><title>Acknowledgements</title><p>The authors apologize to their many colleagues whose valuable contributions they were not able to cite because of space constraints. This work was supported by the Division of Intramural Research of the NIAID, NIH (ZIA AI001175 to M.S.L.). R.A.D. was supported by the UK Medical Research Council (awards MR/S024611 and MR/T029137) and Academy of Medical Sciences (award SBF004_1008). T.M.H. was supported by NIH grants R01 AI093808, R01 AI139632, R21 AI156157 and P30 CA008748 (to Memorial Sloan Kettering Cancer Center).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>The authors contributed equally to all aspects of the article.</p></notes><notes notes-type="peer-review"><title>Peer review</title><sec id="FPar1"><title>Peer review information</title><p id="Par55"><italic toggle="yes">Nature Reviews Immunology</italic> thanks A. Ibrahim, S. Levitz and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.</p></sec></notes><notes id="FPar2" notes-type="COI-statement"><title>Competing interests</title><p id="Par56">T.M.H. participated in a scientific advisory board for Boehringer Ingelheim in 2020. The other authors declare no competing interests.</p></notes><glossary><title>Glossary</title><def-list><def-item id="Glos7"><term>Agglutinin-like sequence 3</term><def><p>(Als3). A <italic toggle="yes">Candida albicans</italic> hyphal protein that facilitates adhesion and invasion in host epithelial and endothelial cells through binding to E-cadherin and N-cadherin, respectively, and that has formed the basis for developing the investigational vaccine NDV-3.</p></def></def-item><def-item id="Glos5"><term>Candidalysin</term><def><p>A pore-forming, cytolytic peptide toxin produced by <italic toggle="yes">Candida albicans</italic> hyphae that promotes damage to oral epithelial cells and is required for virulence during mucosal candidiasis.</p></def></def-item><def-item id="Glos4"><term>Chronic mucocutaneous candidiasis</term><def><p>(CMC). A clinical condition characterized by severe, recurrent and treatment-refractory episodes of candidiasis of mucosal surfaces, skin and/or nails.</p></def></def-item><def-item id="Glos12"><term>Diabetic ketoacidosis</term><def><p>A life-threatening complication of uncontrolled diabetes that is characterized by insulin deficiency driving excessive accumulation of ketone bodies in the blood, which leads to acidosis.</p></def></def-item><def-item id="Glos2"><term>Hyphae</term><def><p>Long filamentous branching structures of certain fungi (for example, <italic toggle="yes">Aspergillus</italic>) that grow by apical extension.</p></def></def-item><def-item id="Glos3"><term>Inborn errors of immunity</term><def><p>Conditions caused by deleterious germ line mutations in single immune-related genes that manifest themselves with various infectious complications with or without other accompanying clinical manifestations, such as autoimmunity, autoinflammation, atopy and/or malignancy.</p></def></def-item><def-item id="Glos9"><term>Kallikrein&#8211;kinin system</term><def><p>A family of serine proteases (kallikreins) that cleave kininogens to generate the kinin peptides bradykinin and kallidin, which as a collective system have important roles in renal homeostasis and blood pressure regulation, with additional roles now emerging during inflammation, immunity and tissue repair.</p></def></def-item><def-item id="Glos11"><term>LC3-associated phagocytosis</term><def><p>A non-canonical autophagy pathway activated downstream of pattern recognition receptors which promotes phagosome maturation and intracellular killing of pathogens within phagocytes and regulates other mononuclear phagocyte functions, such as antigen presentation, efferocytosis and anti-inflammatory cytokine responses.</p></def></def-item><def-item id="Glos6"><term>Natural T<sub>H</sub>17 cell</term><def><p>A type&#160;17 cell subpopulation that develops in the thymus, expresses CD4, TCR&#945;&#946;, ROR&#947;t, CCR6 and IL-23R and, in contrast to inducible T<sub>H</sub>17 cells, is characterized by an intrinsic capacity for rapid activation in response to T cell receptor-independent stimulation in naive hosts.</p></def></def-item><def-item id="Glos10"><term>Trained immunity</term><def><p>The ability of the innate immune system, through epigenetic and metabolic reprogramming, to develop a form of immunological memory that can provide protection against a subsequent challenge with homologous or even heterologous pathogens.</p></def></def-item><def-item id="Glos8"><term>Uraemia</term><def><p>A clinical syndrome characterized by increased concentrations of urea in the blood and electrolyte, volume and metabolic abnormalities that are collectively caused by deteriorating kidney function.</p></def></def-item><def-item id="Glos1"><term>Yeast</term><def><p>A eukaryotic, unicellular fungal organism that reproduces by budding (for example, <italic toggle="yes">Candida</italic>).</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoenigl</surname><given-names>M</given-names></name><etal/></person-group><article-title>COVID-19-associated fungal infections</article-title><source>Nat. Microbiol.</source><year>2022</year><volume>7</volume><fpage>1127</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1038/s41564-022-01172-2</pub-id><pub-id pub-id-type="pmid">35918423</pub-id><pub-id pub-id-type="pmcid">PMC9362108</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name><name name-style="western"><surname>Hohl</surname><given-names>TM</given-names></name></person-group><article-title>Call to action: how to tackle emerging nosocomial fungal infections</article-title><source>Cell Host Microbe</source><year>2020</year><volume>27</volume><fpage>859</fpage><lpage>862</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.04.011</pub-id><pub-id pub-id-type="pmid">32526182</pub-id><pub-id pub-id-type="pmcid">PMC7543769</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salazar</surname><given-names>F</given-names></name><name name-style="western"><surname>Bignell</surname><given-names>E</given-names></name><name name-style="western"><surname>Brown</surname><given-names>GD</given-names></name><name name-style="western"><surname>Cook</surname><given-names>PC</given-names></name><name name-style="western"><surname>Warris</surname><given-names>A</given-names></name></person-group><article-title>Pathogenesis of respiratory viral and fungal coinfections</article-title><source>Clin. Microbiol. Rev.</source><year>2022</year><volume>35</volume><fpage>e0009421</fpage><pub-id pub-id-type="doi">10.1128/CMR.00094-21</pub-id><pub-id pub-id-type="pmid">34788127</pub-id><pub-id pub-id-type="pmcid">PMC8597983</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chow</surname><given-names>NA</given-names></name><etal/></person-group><article-title>Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey</article-title><source>Lancet Infect. Dis.</source><year>2018</year><volume>18</volume><fpage>1377</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30597-8</pub-id><pub-id pub-id-type="pmid">30293877</pub-id><pub-id pub-id-type="pmcid">PMC6556114</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>GD</given-names></name><name name-style="western"><surname>Willment</surname><given-names>JA</given-names></name><name name-style="western"><surname>Whitehead</surname><given-names>L</given-names></name></person-group><article-title>C-type lectins in immunity and homeostasis</article-title><source>Nat. Rev. Immunol.</source><year>2018</year><volume>18</volume><fpage>374</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1038/s41577-018-0004-8</pub-id><pub-id pub-id-type="pmid">29581532</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borriello</surname><given-names>F</given-names></name><etal/></person-group><article-title>An adjuvant strategy enabled by modulation of the physical properties of microbial ligands expands antigen immunogenicity</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>614</fpage><lpage>629 e621</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.009</pub-id><pub-id pub-id-type="pmid">35148840</pub-id><pub-id pub-id-type="pmcid">PMC8857056</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corvilain</surname><given-names>E</given-names></name><name name-style="western"><surname>Casanova</surname><given-names>JL</given-names></name><name name-style="western"><surname>Puel</surname><given-names>A</given-names></name></person-group><article-title>Inherited CARD9 deficiency: invasive disease caused by ascomycete fungi in previously healthy children and adults</article-title><source>J. Clin. Immunol.</source><year>2018</year><volume>38</volume><fpage>656</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1007/s10875-018-0539-2</pub-id><pub-id pub-id-type="pmid">30136218</pub-id><pub-id pub-id-type="pmcid">PMC6157734</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappas</surname><given-names>PG</given-names></name><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name><name name-style="western"><surname>Arendrup</surname><given-names>MC</given-names></name><name name-style="western"><surname>Ostrosky-Zeichner</surname><given-names>L</given-names></name><name name-style="western"><surname>Kullberg</surname><given-names>BJ</given-names></name></person-group><article-title>Invasive candidiasis</article-title><source>Nat. Rev. Dis. Prim.</source><year>2018</year><volume>4</volume><fpage>18026</fpage><pub-id pub-id-type="doi">10.1038/nrdp.2018.26</pub-id><pub-id pub-id-type="pmid">29749387</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name></person-group><article-title>Host control of fungal infections: lessons from basic studies and human cohorts</article-title><source>Annu. Rev. Immunol.</source><year>2018</year><volume>36</volume><fpage>157</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-042617-053318</pub-id><pub-id pub-id-type="pmid">29237128</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaffen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Moutsopoulos</surname><given-names>NM</given-names></name></person-group><article-title>Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity</article-title><source>Sci. Immunol.</source><year>2020</year><volume>5</volume><fpage>eaau4594</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aau4594</pub-id><pub-id pub-id-type="pmid">31901072</pub-id><pub-id pub-id-type="pmcid">PMC7068849</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puel</surname><given-names>A</given-names></name><etal/></person-group><article-title>Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity</article-title><source>Science</source><year>2011</year><volume>332</volume><fpage>65</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1126/science.1200439</pub-id><pub-id pub-id-type="pmid">21350122</pub-id><pub-id pub-id-type="pmcid">PMC3070042</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boisson</surname><given-names>B</given-names></name><etal/></person-group><article-title>An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>676</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.09.002</pub-id><pub-id pub-id-type="pmid">24120361</pub-id><pub-id pub-id-type="pmcid">PMC3873857</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>HR</given-names></name><etal/></person-group><article-title>IL-17 receptor signaling in oral epithelial cells is critical for protection against oropharyngeal candidiasis</article-title><source>Cell Host Microbe</source><year>2016</year><volume>20</volume><fpage>606</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2016.10.001</pub-id><pub-id pub-id-type="pmid">27923704</pub-id><pub-id pub-id-type="pmcid">PMC5147498</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>HR</given-names></name><etal/></person-group><article-title>Oral-resident natural Th17 cells and gammadelta T cells control opportunistic Candida albicans infections</article-title><source>J. Exp. Med.</source><year>2014</year><volume>211</volume><fpage>2075</fpage><lpage>2084</lpage><pub-id pub-id-type="doi">10.1084/jem.20130877</pub-id><pub-id pub-id-type="pmid">25200028</pub-id><pub-id pub-id-type="pmcid">PMC4172215</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>HR</given-names></name><etal/></person-group><article-title>Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis</article-title><source>J. Exp. Med.</source><year>2009</year><volume>206</volume><fpage>299</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1084/jem.20081463</pub-id><pub-id pub-id-type="pmid">19204111</pub-id><pub-id pub-id-type="pmcid">PMC2646568</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>R</given-names></name><etal/></person-group><article-title>Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency</article-title><source>Proc. Natl Acad. Sci. Usa.</source><year>2016</year><volume>113</volume><fpage>E8277</fpage><lpage>E8285</lpage><pub-id pub-id-type="doi">10.1073/pnas.1618300114</pub-id><pub-id pub-id-type="pmid">27930337</pub-id><pub-id pub-id-type="pmcid">PMC5187691</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puel</surname><given-names>A</given-names></name><etal/></person-group><article-title>Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis</article-title><source>Curr. Opin. Allergy Clin. Immunol.</source><year>2012</year><volume>12</volume><fpage>616</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1097/ACI.0b013e328358cc0b</pub-id><pub-id pub-id-type="pmid">23026768</pub-id><pub-id pub-id-type="pmcid">PMC3538358</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oikonomou</surname><given-names>V</given-names></name><name name-style="western"><surname>Break</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Gaffen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Moutsopoulos</surname><given-names>NM</given-names></name><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name></person-group><article-title>Infections in the monogenic autoimmune syndrome APECED</article-title><source>Curr. Opin. Immunol.</source><year>2021</year><volume>72</volume><fpage>286</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2021.07.011</pub-id><pub-id pub-id-type="pmid">34418591</pub-id><pub-id pub-id-type="pmcid">PMC8578378</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davidson</surname><given-names>L</given-names></name><etal/></person-group><article-title>Risk of candidiasis associated with interleukin-17 inhibitors: a real-world observational study of multiple independent sources</article-title><source>Lancet Reg. Health Eur.</source><year>2022</year><volume>13</volume><fpage>100266</fpage><pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100266</pub-id><pub-id pub-id-type="pmid">34950923</pub-id><pub-id pub-id-type="pmcid">PMC8671639</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swidergall</surname><given-names>M</given-names></name><name name-style="western"><surname>LeibundGut-Landmann</surname><given-names>S</given-names></name></person-group><article-title>Immunosurveillance of Candida albicans commensalism by the adaptive immune system</article-title><source>Mucosal Immunol.</source><year>2022</year><volume>15</volume><fpage>829</fpage><lpage>836</lpage><pub-id pub-id-type="doi">10.1038/s41385-022-00536-5</pub-id><pub-id pub-id-type="pmid">35778599</pub-id><pub-id pub-id-type="pmcid">PMC9385492</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggor</surname><given-names>FE</given-names></name><etal/></person-group><article-title>A gut-oral microbiome-driven axis controls oropharyngeal candidiasis through retinoic acid</article-title><source>JCI Insight</source><year>2022</year><volume>7</volume><fpage>e160348</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.160348</pub-id><pub-id pub-id-type="pmid">36134659</pub-id><pub-id pub-id-type="pmcid">PMC9675558</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Oral epithelial cells orchestrate innate type 17 responses to Candida albicans through the virulence factor candidalysin</article-title><source>Sci. Immunol.</source><year>2017</year><volume>2</volume><fpage>eaam8834</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aam8834</pub-id><pub-id pub-id-type="pmid">29101209</pub-id><pub-id pub-id-type="pmcid">PMC5881387</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basso</surname><given-names>P</given-names></name><etal/></person-group><article-title>Deep tissue infection by an invasive human fungal pathogen requires lipid-based suppression of the IL-17 response</article-title><source>Cell Host Microbe</source><year>2022</year><volume>30</volume><fpage>1589</fpage><lpage>1601 e1585</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2022.10.004</pub-id><pub-id pub-id-type="pmid">36323314</pub-id><pub-id pub-id-type="pmcid">PMC9744107</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lisco</surname><given-names>A</given-names></name><etal/></person-group><article-title>Lost in translation: lack of CD4 expression due to a novel genetic defect</article-title><source>J. Infect. Dis.</source><year>2021</year><volume>223</volume><fpage>645</fpage><lpage>654</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiab025</pub-id><pub-id pub-id-type="pmid">33471124</pub-id><pub-id pub-id-type="pmcid">PMC7904290</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cudrici</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Characterization of autoantibodies, immunophenotype and autoimmune disease in a prospective cohort of patients with idiopathic CD4 lymphocytopenia</article-title><source>Clin. Immunol.</source><year>2021</year><volume>224</volume><fpage>108664</fpage><pub-id pub-id-type="doi">10.1016/j.clim.2021.108664</pub-id><pub-id pub-id-type="pmid">33422677</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez-Santos</surname><given-names>N</given-names></name><etal/></person-group><article-title>Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections</article-title><source>Mucosal Immunol.</source><year>2013</year><volume>6</volume><fpage>900</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1038/mi.2012.128</pub-id><pub-id pub-id-type="pmid">23250275</pub-id><pub-id pub-id-type="pmcid">PMC3608691</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swidergall</surname><given-names>M</given-names></name><name name-style="western"><surname>Solis</surname><given-names>NV</given-names></name><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name><name name-style="western"><surname>Filler</surname><given-names>SG</given-names></name></person-group><article-title>EphA2 is an epithelial cell pattern recognition receptor for fungal beta-glucans</article-title><source>Nat. Microbiol.</source><year>2018</year><volume>3</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/s41564-017-0059-5</pub-id><pub-id pub-id-type="pmid">29133884</pub-id><pub-id pub-id-type="pmcid">PMC5736406</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aggor</surname><given-names>FEY</given-names></name><etal/></person-group><article-title>Oral epithelial IL-22/STAT3 signaling licenses IL-17-mediated immunity to oral mucosal candidiasis</article-title><source>Sci. Immunol.</source><year>2020</year><volume>5</volume><fpage>eaba0570</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aba0570</pub-id><pub-id pub-id-type="pmid">32503875</pub-id><pub-id pub-id-type="pmcid">PMC7340112</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Puel</surname><given-names>A</given-names></name><etal/></person-group><article-title>Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I</article-title><source>J. Exp. Med.</source><year>2010</year><volume>207</volume><fpage>291</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1084/jem.20091983</pub-id><pub-id pub-id-type="pmid">20123958</pub-id><pub-id pub-id-type="pmcid">PMC2822614</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kisand</surname><given-names>K</given-names></name><etal/></person-group><article-title>Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines</article-title><source>J. Exp. Med.</source><year>2010</year><volume>207</volume><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1084/jem.20091669</pub-id><pub-id pub-id-type="pmid">20123959</pub-id><pub-id pub-id-type="pmcid">PMC2822605</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Break</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Aberrant type 1 immunity drives susceptibility to mucosal fungal infections</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>eaay5731</fpage><pub-id pub-id-type="doi">10.1126/science.aay5731</pub-id><pub-id pub-id-type="pmid">33446526</pub-id><pub-id pub-id-type="pmcid">PMC8326743</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Toubiana</surname><given-names>J</given-names></name><etal/></person-group><article-title>Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype</article-title><source>Blood</source><year>2016</year><volume>127</volume><fpage>3154</fpage><lpage>3164</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-11-679902</pub-id><pub-id pub-id-type="pmid">27114460</pub-id><pub-id pub-id-type="pmcid">PMC4920021</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yano</surname><given-names>J</given-names></name><etal/></person-group><article-title>Current patient perspectives of vulvovaginal candidiasis: incidence, symptoms, management and post-treatment outcomes</article-title><source>BMC Women&#8217;s Health</source><year>2019</year><volume>19</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.1186/s12905-019-0748-8</pub-id><pub-id pub-id-type="pmid">30925872</pub-id><pub-id pub-id-type="pmcid">PMC6441174</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>JP</given-names></name><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name></person-group><article-title>Pathogenesis and virulence of Candida albicans</article-title><source>Virulence</source><year>2022</year><volume>13</volume><fpage>89</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1080/21505594.2021.2019950</pub-id><pub-id pub-id-type="pmid">34964702</pub-id><pub-id pub-id-type="pmcid">PMC9728475</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>BM</given-names></name><etal/></person-group><article-title>The interleukin (IL) 17R/IL-22R signaling axis is dispensable for Vulvovaginal candidiasis regardless of estrogen status</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>221</volume><fpage>1554</fpage><lpage>1563</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz649</pub-id><pub-id pub-id-type="pmid">31805183</pub-id><pub-id pub-id-type="pmcid">PMC7137889</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>MacAlpine</surname><given-names>J</given-names></name><etal/></person-group><article-title>A small molecule produced by Lactobacillus species blocks Candida albicans filamentation by inhibiting a DYRK1-family kinase</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>6151</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-26390-w</pub-id><pub-id pub-id-type="pmid">34686660</pub-id><pub-id pub-id-type="pmcid">PMC8536679</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>JE</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>A fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis-a phase 2 randomized, double-blind, placebo-controlled trial</article-title><source>Clin. Infect. Dis.</source><year>2018</year><volume>66</volume><fpage>1928</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy185</pub-id><pub-id pub-id-type="pmid">29697768</pub-id><pub-id pub-id-type="pmcid">PMC5982716</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ibrahim</surname><given-names>AS</given-names></name><etal/></person-group><article-title>NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>5549</fpage><lpage>5556</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.09.016</pub-id><pub-id pub-id-type="pmid">24063977</pub-id><pub-id pub-id-type="pmcid">PMC3866209</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashem</surname><given-names>SW</given-names></name><etal/></person-group><article-title>Nociceptive sensory fibers drive interleukin-23 production from CD301b<sup>+</sup> dermal dendritic cells and drive protective cutaneous immunity</article-title><source>Immunity</source><year>2015</year><volume>43</volume><fpage>515</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.08.016</pub-id><pub-id pub-id-type="pmid">26377898</pub-id><pub-id pub-id-type="pmcid">PMC4607048</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Cutaneous TRPV1<sup>+</sup> neurons trigger protective innate type 17 anticipatory immunity</article-title><source>Cell</source><year>2019</year><volume>178</volume><fpage>919</fpage><lpage>932 e914</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.06.022</pub-id><pub-id pub-id-type="pmid">31353219</pub-id><pub-id pub-id-type="pmcid">PMC6788801</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonardi</surname><given-names>I</given-names></name><etal/></person-group><article-title>Mucosal fungi promote gut barrier function and social behavior via type 17 immunity</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>831</fpage><lpage>846 e814</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.017</pub-id><pub-id pub-id-type="pmid">35176228</pub-id><pub-id pub-id-type="pmcid">PMC8897247</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huh</surname><given-names>JR</given-names></name><name name-style="western"><surname>Veiga-Fernandes</surname><given-names>H</given-names></name></person-group><article-title>Neuroimmune circuits in inter-organ communication</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>217</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0247-z</pub-id><pub-id pub-id-type="pmid">31848462</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Activation of HIF-1alpha and LL-37 by commensal bacteria inhibits Candida albicans colonization</article-title><source>Nat. Med.</source><year>2015</year><volume>21</volume><fpage>808</fpage><lpage>814</lpage><pub-id pub-id-type="doi">10.1038/nm.3871</pub-id><pub-id pub-id-type="pmid">26053625</pub-id><pub-id pub-id-type="pmcid">PMC4496259</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drummond</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Long-term antibiotic exposure promotes mortality after systemic fungal infection by driving lymphocyte dysfunction and systemic escape of commensal bacteria</article-title><source>Cell Host Microbe</source><year>2022</year><volume>30</volume><fpage>1020</fpage><lpage>1033.e6</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2022.04.013</pub-id><pub-id pub-id-type="pmid">35568028</pub-id><pub-id pub-id-type="pmcid">PMC9283303</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glocker</surname><given-names>EO</given-names></name><etal/></person-group><article-title>A homozygous CARD9 mutation in a family with susceptibility to fungal infections</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>361</volume><fpage>1727</fpage><lpage>1735</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0810719</pub-id><pub-id pub-id-type="pmid">19864672</pub-id><pub-id pub-id-type="pmcid">PMC2793117</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drummond</surname><given-names>RA</given-names></name><etal/></person-group><article-title>CARD9<sup>+</sup> microglia promote antifungal immunity via IL-1&#946; - and CXCL1-mediated neutrophil recruitment</article-title><source>Nat. Immunol.</source><year>2019</year><volume>20</volume><fpage>559</fpage><lpage>570</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0377-2</pub-id><pub-id pub-id-type="pmid">30996332</pub-id><pub-id pub-id-type="pmcid">PMC6494474</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jodele</surname><given-names>S</given-names></name><etal/></person-group><article-title>Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab</article-title><source>Blood</source><year>2020</year><volume>135</volume><fpage>1049</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">31932840</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2019004218</pub-id><pub-id pub-id-type="pmcid">PMC7099329</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bar</surname><given-names>E</given-names></name><name name-style="western"><surname>Whitney</surname><given-names>PG</given-names></name><name name-style="western"><surname>Moor</surname><given-names>K</given-names></name><name name-style="western"><surname>Reis e Sousa</surname><given-names>C</given-names></name><name name-style="western"><surname>LeibundGut-Landmann</surname><given-names>S</given-names></name></person-group><article-title>IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells</article-title><source>Immunity</source><year>2014</year><volume>40</volume><fpage>117</fpage><lpage>127</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.12.002</pub-id><pub-id pub-id-type="pmid">24412614</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dominguez-Andres</surname><given-names>J</given-names></name><etal/></person-group><article-title>Inflammatory Ly6Chigh monocytes protect against candidiasis through IL-15-driven NK cell/neutrophil activation</article-title><source>Immunity</source><year>2017</year><volume>46</volume><fpage>1059</fpage><lpage>1072 e1054</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2017.05.009</pub-id><pub-id pub-id-type="pmid">28636955</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>L</given-names></name><etal/></person-group><article-title>Effect of granulocyte-macrophage colony-stimulating factor on prevention and treatment of invasive fungal disease in recipients of allogeneic stem-cell transplantation: a prospective multicenter randomized phase IV trial</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>3999</fpage><lpage>4006</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.60.5121</pub-id><pub-id pub-id-type="pmid">26392095</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Fungal sensing enhances neutrophil metabolic fitness by regulating antifungal Glut1 activity</article-title><source>Cell Host Microbe</source><year>2022</year><volume>30</volume><fpage>530</fpage><lpage>544 e536</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2022.02.017</pub-id><pub-id pub-id-type="pmid">35316647</pub-id><pub-id pub-id-type="pmcid">PMC9026661</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jawale</surname><given-names>CV</given-names></name><etal/></person-group><article-title>Restoring glucose uptake rescues neutrophil dysfunction and protects against systemic fungal infection in mouse models of kidney disease</article-title><source>Sci. Transl. Med.</source><year>2020</year><volume>12</volume><fpage>eaay5691</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aay5691</pub-id><pub-id pub-id-type="pmid">32554707</pub-id><pub-id pub-id-type="pmcid">PMC7879380</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Candon</surname><given-names>S</given-names></name><etal/></person-group><article-title>Chronic disseminated candidiasis during hematological malignancies: an immune reconstitution inflammatory syndrome with expansion of pathogen-specific T helper type 1 cells</article-title><source>J. Infect. Dis.</source><year>2020</year><volume>221</volume><fpage>1907</fpage><lpage>1916</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz688</pub-id><pub-id pub-id-type="pmid">31879764</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garg</surname><given-names>AV</given-names></name><etal/></person-group><article-title>MCPIP1 endoribonuclease activity negatively regulates interleukin-17-mediated signaling and inflammation</article-title><source>Immunity</source><year>2015</year><volume>43</volume><fpage>475</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2015.07.021</pub-id><pub-id pub-id-type="pmid">26320658</pub-id><pub-id pub-id-type="pmcid">PMC4575280</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Chemokine receptor Ccr1 drives neutrophil-mediated kidney immunopathology and mortality in invasive candidiasis</article-title><source>PLoS Pathog.</source><year>2012</year><volume>8</volume><fpage>e1002865</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1002865</pub-id><pub-id pub-id-type="pmid">22916017</pub-id><pub-id pub-id-type="pmcid">PMC3420964</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Del Fresno</surname><given-names>C</given-names></name><etal/></person-group><article-title>DNGR-1 in dendritic cells limits tissue damage by dampening neutrophil recruitment</article-title><source>Science</source><year>2018</year><volume>362</volume><fpage>351</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1126/science.aan8423</pub-id><pub-id pub-id-type="pmid">30337411</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Progranulin aggravates lethal Candida albicans sepsis by regulating inflammatory response and antifungal immunity</article-title><source>PLoS Pathog.</source><year>2022</year><volume>18</volume><fpage>e1010873</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1010873</pub-id><pub-id pub-id-type="pmid">36121866</pub-id><pub-id pub-id-type="pmcid">PMC9521894</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramani</surname><given-names>K</given-names></name><etal/></person-group><article-title>The kallikrein-kinin system: a novel mediator of IL-17-driven anti-Candida immunity in the kidney</article-title><source>PLoS Pathog.</source><year>2016</year><volume>12</volume><fpage>e1005952</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1005952</pub-id><pub-id pub-id-type="pmid">27814401</pub-id><pub-id pub-id-type="pmcid">PMC5096720</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name><etal/></person-group><article-title>CX3CR1-dependent renal macrophage survival promotes Candida control and host survival</article-title><source>J. Clin. Invest.</source><year>2013</year><volume>123</volume><fpage>5035</fpage><lpage>5051</lpage><pub-id pub-id-type="doi">10.1172/JCI71307</pub-id><pub-id pub-id-type="pmid">24177428</pub-id><pub-id pub-id-type="pmcid">PMC3859390</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngo</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Inflammatory monocytes mediate early and organ-specific innate defense during systemic candidiasis</article-title><source>J. Infect. Dis.</source><year>2014</year><volume>209</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit413</pub-id><pub-id pub-id-type="pmid">23922372</pub-id><pub-id pub-id-type="pmcid">PMC3864383</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>SC</given-names></name><etal/></person-group><article-title>mTOR- and HIF-1alpha-mediated aerobic glycolysis as metabolic basis for trained immunity</article-title><source>Science</source><year>2014</year><volume>345</volume><fpage>1250684</fpage><pub-id pub-id-type="doi">10.1126/science.1250684</pub-id><pub-id pub-id-type="pmid">25258083</pub-id><pub-id pub-id-type="pmcid">PMC4226238</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><etal/></person-group><article-title>JNK1 negatively controls antifungal innate immunity by suppressing CD23 expression</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>337</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/nm.4260</pub-id><pub-id pub-id-type="pmid">28112734</pub-id><pub-id pub-id-type="pmcid">PMC5592785</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A/F and TGF-beta</article-title><source>Sci. Immunol.</source><year>2019</year><volume>4</volume><fpage>eaax7965</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aax7965</pub-id><pub-id pub-id-type="pmid">31784499</pub-id><pub-id pub-id-type="pmcid">PMC7014825</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitzpatrick</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Gut-educated IgA plasma cells defend the meningeal venous sinuses</article-title><source>Nature</source><year>2020</year><volume>587</volume><fpage>472</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2886-4</pub-id><pub-id pub-id-type="pmid">33149302</pub-id><pub-id pub-id-type="pmcid">PMC7748383</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>V</given-names></name><etal/></person-group><article-title>Immunochip SNP array identifies novel genetic variants conferring susceptibility to candidaemia</article-title><source>Nat. Commun.</source><year>2014</year><volume>5</volume><fpage>4675</fpage><pub-id pub-id-type="doi">10.1038/ncomms5675</pub-id><pub-id pub-id-type="pmid">25197941</pub-id><pub-id pub-id-type="pmcid">PMC5142444</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Latge</surname><given-names>JP</given-names></name><name name-style="western"><surname>Chamilos</surname><given-names>G</given-names></name></person-group><article-title>Aspergillus fumigatus and aspergillosis in 2019</article-title><source>Clin. Microbiol. Rev.</source><year>2019</year><volume>33</volume><fpage>e00140-18</fpage><pub-id pub-id-type="doi">10.1128/CMR.00140-18</pub-id><pub-id pub-id-type="pmid">31722890</pub-id><pub-id pub-id-type="pmcid">PMC6860006</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espinosa</surname><given-names>V</given-names></name><etal/></person-group><article-title>Inflammatory monocytes orchestrate innate antifungal immunity in the lung</article-title><source>PLoS Pathog.</source><year>2014</year><volume>10</volume><fpage>e1003940</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1003940</pub-id><pub-id pub-id-type="pmid">24586155</pub-id><pub-id pub-id-type="pmcid">PMC3930594</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>S</given-names></name><etal/></person-group><article-title>Human natural killer cells exhibit direct activity against Aspergillus fumigatus hyphae, but not against resting conidia</article-title><source>J. Infect. Dis.</source><year>2011</year><volume>203</volume><fpage>430</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiq062</pub-id><pub-id pub-id-type="pmid">21208932</pub-id><pub-id pub-id-type="pmcid">PMC3071101</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seif</surname><given-names>M</given-names></name><etal/></person-group><article-title>CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models</article-title><source>Sci. Transl. Med.</source><year>2022</year><volume>14</volume><fpage>eabh1209</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abh1209</pub-id><pub-id pub-id-type="pmid">36170447</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cadena</surname><given-names>J</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>GR</given-names><suffix>III</suffix></name><name name-style="western"><surname>Patterson</surname><given-names>TF</given-names></name></person-group><article-title>Aspergillosis: epidemiology, diagnosis, and treatment</article-title><source>Infect. Dis. Clin. North. Am.</source><year>2021</year><volume>35</volume><fpage>415</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2021.03.008</pub-id><pub-id pub-id-type="pmid">34016284</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agarwal</surname><given-names>R</given-names></name><etal/></person-group><article-title>Allergic bronchopulmonary aspergillosis</article-title><source>Clin. Chest Med.</source><year>2022</year><volume>43</volume><fpage>99</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.ccm.2021.12.002</pub-id><pub-id pub-id-type="pmid">35236565</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Philippe</surname><given-names>B</given-names></name><etal/></person-group><article-title>Killing of Aspergillus fumigatus by alveolar macrophages is mediated by reactive oxidant intermediates</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>3034</fpage><lpage>3042</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.6.3034-3042.2003</pub-id><pub-id pub-id-type="pmid">12761080</pub-id><pub-id pub-id-type="pmcid">PMC155721</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hohl</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Aspergillus fumigatus triggers inflammatory responses by stage-specific beta-glucan display</article-title><source>PLoS Pathog.</source><year>2005</year><volume>1</volume><fpage>e30</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.0010030</pub-id><pub-id pub-id-type="pmid">16304610</pub-id><pub-id pub-id-type="pmcid">PMC1287910</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aimanianda</surname><given-names>V</given-names></name><etal/></person-group><article-title>Surface hydrophobin prevents immune recognition of airborne fungal spores</article-title><source>Nature</source><year>2009</year><volume>460</volume><fpage>1117</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1038/nature08264</pub-id><pub-id pub-id-type="pmid">19713928</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doni</surname><given-names>A</given-names></name><etal/></person-group><article-title>Serum amyloid P component is an essential element of resistance against Aspergillus fumigatus</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>3739</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-24021-y</pub-id><pub-id pub-id-type="pmid">34145258</pub-id><pub-id pub-id-type="pmcid">PMC8213769</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garlanda</surname><given-names>C</given-names></name><etal/></person-group><article-title>Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>182</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/nature01195</pub-id><pub-id pub-id-type="pmid">12432394</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stappers</surname><given-names>MHT</given-names></name><etal/></person-group><article-title>Recognition of DHN-melanin by a C-type lectin receptor is required for immunity to Aspergillus</article-title><source>Nature</source><year>2018</year><volume>555</volume><fpage>382</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1038/nature25974</pub-id><pub-id pub-id-type="pmid">29489751</pub-id><pub-id pub-id-type="pmcid">PMC5857201</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Aspergillus fumigatus CalA binds to integrin alpha5beta1 and mediates host cell invasion</article-title><source>Nat. Microbiol.</source><year>2016</year><volume>2</volume><fpage>16211</fpage><pub-id pub-id-type="doi">10.1038/nmicrobiol.2016.211</pub-id><pub-id pub-id-type="pmid">27841851</pub-id><pub-id pub-id-type="pmcid">PMC5495140</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leal</surname><given-names>SM</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>Fungal antioxidant pathways promote survival against neutrophils during infection</article-title><source>J. Clin. Invest.</source><year>2012</year><volume>122</volume><fpage>2482</fpage><lpage>2498</lpage><pub-id pub-id-type="doi">10.1172/JCI63239</pub-id><pub-id pub-id-type="pmid">22706306</pub-id><pub-id pub-id-type="pmcid">PMC3534057</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shlezinger</surname><given-names>N</given-names></name><etal/></person-group><article-title>Sterilizing immunity in the lung relies on targeting fungal apoptosis-like programmed cell death</article-title><source>Science</source><year>2017</year><volume>357</volume><fpage>1037</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1126/science.aan0365</pub-id><pub-id pub-id-type="pmid">28883073</pub-id><pub-id pub-id-type="pmcid">PMC5628051</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>International Chronic Granulomatous Disease Cooperative Study Group.</collab></person-group><article-title>A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease</article-title><source>N. Engl. J. Med.</source><year>1991</year><volume>324</volume><fpage>509</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.1056/NEJM199102213240801</pub-id><pub-id pub-id-type="pmid">1846940</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akoumianaki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Aspergillus cell wall melanin blocks LC3-associated phagocytosis to promote pathogenicity</article-title><source>Cell Host Microbe</source><year>2016</year><volume>19</volume><fpage>79</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2015.12.002</pub-id><pub-id pub-id-type="pmid">26749442</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goncalves</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Phagosomal removal of fungal melanin reprograms macrophage metabolism to promote antifungal immunity</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>2282</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16120-z</pub-id><pub-id pub-id-type="pmid">32385235</pub-id><pub-id pub-id-type="pmcid">PMC7210971</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group><article-title>During aspergillus infection, monocyte-derived DCs, neutrophils, and plasmacytoid DCs enhance innate immune defense through CXCR3-dependent crosstalk</article-title><source>Cell Host Microbe</source><year>2020</year><volume>28</volume><fpage>104</fpage><lpage>116 e104</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.05.002</pub-id><pub-id pub-id-type="pmid">32485165</pub-id><pub-id pub-id-type="pmcid">PMC7263227</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jhingran</surname><given-names>A</given-names></name><etal/></person-group><article-title>Compartment-specific and sequential role of MyD88 and CARD9 in chemokine induction and innate defense during respiratory fungal infection</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><fpage>e1004589</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1004589</pub-id><pub-id pub-id-type="pmid">25621893</pub-id><pub-id pub-id-type="pmcid">PMC4306481</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caffrey</surname><given-names>AK</given-names></name><etal/></person-group><article-title>IL-1alpha signaling is critical for leukocyte recruitment after pulmonary Aspergillus fumigatus challenge</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><fpage>e1004625</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1004625</pub-id><pub-id pub-id-type="pmid">25629406</pub-id><pub-id pub-id-type="pmcid">PMC4309569</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rieber</surname><given-names>N</given-names></name><etal/></person-group><article-title>Extrapulmonary Aspergillus infection in patients with CARD9 deficiency</article-title><source>JCI Insight</source><year>2016</year><volume>1</volume><fpage>e89890</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.89890</pub-id><pub-id pub-id-type="pmid">27777981</pub-id><pub-id pub-id-type="pmcid">PMC5070961</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>MDA5 is an essential sensor of a pathogen-associated molecular pattern associated with vitality that is necessary for host resistance against Aspergillus fumigatus</article-title><source>J. Immunol.</source><year>2020</year><volume>205</volume><fpage>3058</fpage><lpage>3070</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2000802</pub-id><pub-id pub-id-type="pmid">33087405</pub-id><pub-id pub-id-type="pmcid">PMC7785165</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caffrey-Carr</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Host-derived leukotriene B4 is critical for resistance against invasive pulmonary aspergillosis</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>1984</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.01984</pub-id><pub-id pub-id-type="pmid">29375586</pub-id><pub-id pub-id-type="pmcid">PMC5768911</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snarr</surname><given-names>BD</given-names></name><etal/></person-group><article-title>Galectin-3 enhances neutrophil motility and extravasation into the airways during Aspergillus fumigatus infection</article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><fpage>e1008741</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1008741</pub-id><pub-id pub-id-type="pmid">32750085</pub-id><pub-id pub-id-type="pmcid">PMC7428289</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hohl</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Inflammatory monocytes facilitate adaptive CD4 T cell responses during respiratory fungal infection</article-title><source>Cell Host Microbe</source><year>2009</year><volume>6</volume><fpage>470</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2009.10.007</pub-id><pub-id pub-id-type="pmid">19917501</pub-id><pub-id pub-id-type="pmcid">PMC2785497</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espinosa</surname><given-names>V</given-names></name><etal/></person-group><article-title>Type III interferon is a critical regulator of innate antifungal immunity</article-title><source>Sci. Immunol.</source><year>2017</year><volume>2</volume><fpage>eaan5357</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aan5357</pub-id><pub-id pub-id-type="pmid">28986419</pub-id><pub-id pub-id-type="pmcid">PMC5880030</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Espinosa</surname><given-names>V</given-names></name><etal/></person-group><article-title>Cutting edge: neutrophils license the maturation of monocytes into effective antifungal effectors</article-title><source>J. Immunol.</source><year>2022</year><volume>209</volume><fpage>1827</fpage><lpage>1831</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2200430</pub-id><pub-id pub-id-type="pmid">36216513</pub-id><pub-id pub-id-type="pmcid">PMC10115354</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasahara</surname><given-names>S</given-names></name><etal/></person-group><article-title>Role of granulocyte-macrophage colony-stimulating factor signaling in regulating neutrophil antifungal activity and the oxidative burst during respiratory fungal challenge</article-title><source>J. Infect. Dis.</source><year>2016</year><volume>213</volume><fpage>1289</fpage><lpage>1298</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw054</pub-id><pub-id pub-id-type="pmid">26908736</pub-id><pub-id pub-id-type="pmcid">PMC4799674</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Punatar</surname><given-names>AD</given-names></name><name name-style="western"><surname>Kusne</surname><given-names>S</given-names></name><name name-style="western"><surname>Blair</surname><given-names>JE</given-names></name><name name-style="western"><surname>Seville</surname><given-names>MT</given-names></name><name name-style="western"><surname>Vikram</surname><given-names>HR</given-names></name></person-group><article-title>Opportunistic infections in patients with pulmonary alveolar proteinosis</article-title><source>J. Infect.</source><year>2012</year><volume>65</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1016/j.jinf.2012.03.020</pub-id><pub-id pub-id-type="pmid">22484272</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zarember</surname><given-names>KA</given-names></name><name name-style="western"><surname>Sugui</surname><given-names>JA</given-names></name><name name-style="western"><surname>Chang</surname><given-names>YC</given-names></name><name name-style="western"><surname>Kwon-Chung</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Gallin</surname><given-names>JI</given-names></name></person-group><article-title>Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion</article-title><source>J. Immunol.</source><year>2007</year><volume>178</volume><fpage>6367</fpage><lpage>6373</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.10.6367</pub-id><pub-id pub-id-type="pmid">17475866</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>HL</given-names></name><etal/></person-group><article-title>Zinc and manganese chelation by neutrophil S100A8/A9 (calprotectin) limits extracellular aspergillus fumigatus hyphal growth and corneal infection</article-title><source>J. Immunol.</source><year>2016</year><volume>196</volume><fpage>336</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1502037</pub-id><pub-id pub-id-type="pmid">26582948</pub-id><pub-id pub-id-type="pmcid">PMC4684987</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunha</surname><given-names>C</given-names></name><etal/></person-group><article-title>Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>370</volume><fpage>421</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1211161</pub-id><pub-id pub-id-type="pmid">24476432</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>CE</given-names></name><etal/></person-group><article-title>Validation of single nucleotide polymorphisms in invasive aspergillosis following hematopoietic cell transplantation</article-title><source>Blood</source><year>2017</year><volume>129</volume><fpage>2693</fpage><lpage>2701</lpage><pub-id pub-id-type="doi">10.1182/blood-2016-10-743294</pub-id><pub-id pub-id-type="pmid">28270451</pub-id><pub-id pub-id-type="pmcid">PMC5428460</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma</article-title><source>Cancer Cell</source><year>2017</year><volume>31</volume><fpage>833</fpage><lpage>843 e835</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.04.012</pub-id><pub-id pub-id-type="pmid">28552327</pub-id><pub-id pub-id-type="pmcid">PMC5571650</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghez</surname><given-names>D</given-names></name><etal/></person-group><article-title>Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib</article-title><source>Blood</source><year>2018</year><volume>131</volume><fpage>1955</fpage><lpage>1959</lpage><pub-id pub-id-type="doi">10.1182/blood-2017-11-818286</pub-id><pub-id pub-id-type="pmid">29437588</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbst</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus</article-title><source>EMBO Mol. Med.</source><year>2015</year><volume>7</volume><fpage>240</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.15252/emmm.201404556</pub-id><pub-id pub-id-type="pmid">25637383</pub-id><pub-id pub-id-type="pmcid">PMC4364943</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roden</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Epidemiology and outcome of zygomycosis: a review of 929 reported cases</article-title><source>Clin. Infect. Dis.</source><year>2005</year><volume>41</volume><fpage>634</fpage><lpage>653</lpage><pub-id pub-id-type="doi">10.1086/432579</pub-id><pub-id pub-id-type="pmid">16080086</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soliman</surname><given-names>SSM</given-names></name><etal/></person-group><article-title>Mucoricin is a ricin-like toxin that is critical for the pathogenesis of mucormycosis</article-title><source>Nat. Microbiol.</source><year>2021</year><volume>6</volume><fpage>313</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-00837-0</pub-id><pub-id pub-id-type="pmid">33462434</pub-id><pub-id pub-id-type="pmcid">PMC7914224</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><etal/></person-group><article-title>The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice</article-title><source>J. Clin. Invest.</source><year>2010</year><volume>120</volume><fpage>1914</fpage><lpage>1924</lpage><pub-id pub-id-type="doi">10.1172/JCI42164</pub-id><pub-id pub-id-type="pmid">20484814</pub-id><pub-id pub-id-type="pmcid">PMC2877958</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebremariam</surname><given-names>T</given-names></name><etal/></person-group><article-title>CotH3 mediates fungal invasion of host cells during mucormycosis</article-title><source>J. Clin. Invest.</source><year>2014</year><volume>124</volume><fpage>237</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1172/JCI71349</pub-id><pub-id pub-id-type="pmid">24355926</pub-id><pub-id pub-id-type="pmcid">PMC3871245</pub-id></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gebremariam</surname><given-names>T</given-names></name><etal/></person-group><article-title>Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis</article-title><source>J. Clin. Invest.</source><year>2016</year><volume>126</volume><fpage>2280</fpage><lpage>2294</lpage><pub-id pub-id-type="doi">10.1172/JCI82744</pub-id><pub-id pub-id-type="pmid">27159390</pub-id><pub-id pub-id-type="pmcid">PMC4887168</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alqarihi</surname><given-names>A</given-names></name><etal/></person-group><article-title>GRP78 and integrins play different roles in host cell invasion during mucormycosis</article-title><source>mBio</source><year>2020</year><volume>11</volume><fpage>e01087-20</fpage><pub-id pub-id-type="doi">10.1128/mBio.01087-20</pub-id><pub-id pub-id-type="pmid">32487760</pub-id><pub-id pub-id-type="pmcid">PMC7267888</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watkins</surname><given-names>TN</given-names></name><etal/></person-group><article-title>Inhibition of EGFR signaling protects from mucormycosis</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e01384-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.01384-18</pub-id><pub-id pub-id-type="pmid">30108171</pub-id><pub-id pub-id-type="pmcid">PMC6094478</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrianaki</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Iron restriction inside macrophages regulates pulmonary host defense against Rhizopus species</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>3333</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-05820-2</pub-id><pub-id pub-id-type="pmid">30127354</pub-id><pub-id pub-id-type="pmcid">PMC6102248</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siqueira</surname><given-names>IM</given-names></name><etal/></person-group><article-title>Early immune response against Fonsecaea pedrosoi requires dectin-2-mediated Th17 activity, whereas Th1 response, aided by Treg cells, is crucial for fungal clearance in later stage of experimental chromoblastomycosis</article-title><source>PLoS Negl. Trop. Dis.</source><year>2020</year><volume>14</volume><fpage>e0008386</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0008386</pub-id><pub-id pub-id-type="pmid">32542003</pub-id><pub-id pub-id-type="pmcid">PMC7316354</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teixeira de Sousa Mda</surname><given-names>G</given-names></name><name name-style="western"><surname>Ghosn</surname><given-names>EE</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>SR</given-names></name></person-group><article-title>Absence of CD4<sup>+</sup> T cells impairs host defence of mice infected with Fonsecaea pedrosoi</article-title><source>Scand. J. Immunol.</source><year>2006</year><volume>64</volume><fpage>595</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3083.2006.01846.x</pub-id><pub-id pub-id-type="pmid">17083615</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sousa Mda</surname><given-names>G</given-names></name><etal/></person-group><article-title>Restoration of pattern recognition receptor costimulation to treat chromoblastomycosis, a chronic fungal infection of the skin</article-title><source>Cell Host Microbe</source><year>2011</year><volume>9</volume><fpage>436</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2011.04.005</pub-id><pub-id pub-id-type="pmid">21575914</pub-id><pub-id pub-id-type="pmcid">PMC3098964</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Sousa Mda</surname><given-names>G</given-names></name><etal/></person-group><article-title>Topical application of imiquimod as a treatment for chromoblastomycosis</article-title><source>Clin. Infect. Dis.</source><year>2014</year><volume>58</volume><fpage>1734</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1093/cid/ciu168</pub-id><pub-id pub-id-type="pmid">24633683</pub-id><pub-id pub-id-type="pmcid">PMC4036686</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Revankar</surname><given-names>SG</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>JE</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>DA</given-names></name><name name-style="western"><surname>Pullen</surname><given-names>R</given-names></name><name name-style="western"><surname>Rinaldi</surname><given-names>MG</given-names></name></person-group><article-title>Disseminated phaeohyphomycosis: review of an emerging mycosis</article-title><source>Clin. Infect. Dis.</source><year>2002</year><volume>34</volume><fpage>467</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1086/338636</pub-id><pub-id pub-id-type="pmid">11797173</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kainer</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Fungal infections associated with contaminated methylprednisolone in Tennessee</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>367</volume><fpage>2194</fpage><lpage>2203</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1212972</pub-id><pub-id pub-id-type="pmid">23131029</pub-id><pub-id pub-id-type="pmcid">PMC4669562</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drummond</surname><given-names>RA</given-names></name><etal/></person-group><article-title>Human dectin-1 deficiency impairs macrophage-mediated defense against phaeohyphomycosis</article-title><source>J. Clin. Invest.</source><year>2022</year><volume>132</volume><fpage>e159348</fpage><pub-id pub-id-type="doi">10.1172/JCI159348</pub-id><pub-id pub-id-type="pmid">36377664</pub-id><pub-id pub-id-type="pmcid">PMC9663159</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazzurco</surname><given-names>JD</given-names></name><name name-style="western"><surname>Ramirez</surname><given-names>J</given-names></name><name name-style="western"><surname>Fivenson</surname><given-names>DP</given-names></name></person-group><article-title>Phaeohyphomycosis caused by Phaeoacremonium species in a patient taking infliximab</article-title><source>J. Am. Acad. Dermatol.</source><year>2012</year><volume>66</volume><fpage>333</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2010.04.015</pub-id><pub-id pub-id-type="pmid">22243731</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casadevall</surname><given-names>A</given-names></name></person-group><article-title>Immunity to invasive fungal diseases</article-title><source>Annu. Rev. Immunol.</source><year>2022</year><volume>40</volume><fpage>121</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-101220-034306</pub-id><pub-id pub-id-type="pmid">35007128</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erwig</surname><given-names>LP</given-names></name><name name-style="western"><surname>Gow</surname><given-names>NA</given-names></name></person-group><article-title>Interactions of fungal pathogens with phagocytes</article-title><source>Nat. Rev. Microbiol.</source><year>2016</year><volume>14</volume><fpage>163</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2015.21</pub-id><pub-id pub-id-type="pmid">26853116</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Browne</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Adult-onset immunodeficiency in Thailand and Taiwan</article-title><source>N. Engl. J. Med.</source><year>2012</year><volume>367</volume><fpage>725</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1111160</pub-id><pub-id pub-id-type="pmid">22913682</pub-id><pub-id pub-id-type="pmcid">PMC4190026</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Browne</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Anti-CD20 (rituximab) therapy for anti-IFN-gamma autoantibody-associated nontuberculous mycobacterial infection</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>3933</fpage><lpage>3939</lpage><pub-id pub-id-type="doi">10.1182/blood-2011-12-395707</pub-id><pub-id pub-id-type="pmid">22403254</pub-id><pub-id pub-id-type="pmcid">PMC3350360</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ochoa</surname><given-names>S</given-names></name><etal/></person-group><article-title>Daratumumab (anti-CD38) for treatment of disseminated nontuberculous mycobacteria in a patient with anti-interferon-gamma autoantibodies</article-title><source>Clin. Infect. Dis.</source><year>2021</year><volume>72</volume><fpage>2206</fpage><lpage>2208</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1086</pub-id><pub-id pub-id-type="pmid">32745179</pub-id><pub-id pub-id-type="pmcid">PMC8204786</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francoise</surname><given-names>U</given-names></name><name name-style="western"><surname>Lafont</surname><given-names>E</given-names></name><name name-style="western"><surname>Suarez</surname><given-names>F</given-names></name><name name-style="western"><surname>Lanternier</surname><given-names>F</given-names></name><name name-style="western"><surname>Lortholary</surname><given-names>O</given-names></name></person-group><article-title>Disseminated cryptococcosis in a patient with CD40 ligand deficiency</article-title><source>J. Clin. Immunol.</source><year>2022</year><volume>42</volume><fpage>1622</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.1007/s10875-022-01329-y</pub-id><pub-id pub-id-type="pmid">35932410</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinh</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia</article-title><source>Blood</source><year>2010</year><volume>115</volume><fpage>1519</fpage><lpage>1529</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-03-208629</pub-id><pub-id pub-id-type="pmid">20040766</pub-id><pub-id pub-id-type="pmcid">PMC2830758</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Na</surname><given-names>YR</given-names></name><etal/></person-group><article-title>GM-CSF induces inflammatory macrophages by regulating glycolysis and lipid metabolism</article-title><source>J. Immunol.</source><year>2016</year><volume>197</volume><fpage>4101</fpage><pub-id pub-id-type="doi">10.4049/jimmunol.1600745</pub-id><pub-id pub-id-type="pmid">27742831</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saijo</surname><given-names>T</given-names></name><etal/></person-group><article-title>Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients</article-title><source>mBio</source><year>2014</year><volume>5</volume><fpage>e00912-14</fpage><pub-id pub-id-type="doi">10.1128/mBio.00912-14</pub-id><pub-id pub-id-type="pmid">24643864</pub-id><pub-id pub-id-type="pmcid">PMC3967522</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kannambath</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genome-wide association study identifies novel colony stimulating factor 1 locus conferring susceptibility to cryptococcosis in human immunodeficiency virus-infected South Africans</article-title><source>Open Forum Infect. Dis.</source><year>2020</year><volume>7</volume><fpage>ofaa489</fpage><pub-id pub-id-type="doi">10.1093/ofid/ofaa489</pub-id><pub-id pub-id-type="pmid">33269293</pub-id><pub-id pub-id-type="pmcid">PMC7686661</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmore</surname><given-names>MRP</given-names></name><etal/></person-group><article-title>Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain</article-title><source>Neuron</source><year>2014</year><volume>82</volume><fpage>380</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2014.02.040</pub-id><pub-id pub-id-type="pmid">24742461</pub-id><pub-id pub-id-type="pmcid">PMC4161285</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryan</surname><given-names>AM</given-names></name><etal/></person-group><article-title>FTY720 reactivates cryptococcal granulomas in mice through S1P receptor 3 on macrophages</article-title><source>J. Clin. Invest.</source><year>2020</year><volume>130</volume><fpage>4546</fpage><lpage>4560</lpage><pub-id pub-id-type="doi">10.1172/JCI136068</pub-id><pub-id pub-id-type="pmid">32484801</pub-id><pub-id pub-id-type="pmcid">PMC7456236</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SC</given-names></name><name name-style="western"><surname>Dickson</surname><given-names>DW</given-names></name><name name-style="western"><surname>Casadevall</surname><given-names>A</given-names></name></person-group><article-title>Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathogenetic implications</article-title><source>Hum. Pathol.</source><year>1996</year><volume>27</volume><fpage>839</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1016/S0046-8177(96)90459-1</pub-id><pub-id pub-id-type="pmid">8760020</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>SA</given-names></name><name name-style="western"><surname>May</surname><given-names>RC</given-names></name></person-group><article-title>The human fungal pathogen Cryptococcus neoformans escapes macrophages by a phagosome emptying mechanism that is inhibited by Arp2/3 complex-mediated actin polymerisation</article-title><source>PLoS Pathog.</source><year>2010</year><volume>6</volume><fpage>e1001041</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1001041</pub-id><pub-id pub-id-type="pmid">20714349</pub-id><pub-id pub-id-type="pmcid">PMC2920849</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Cryptococcus neoformans urease affects the outcome of intracellular pathogenesis by modulating phagolysosomal pH</article-title><source>PLoS Pathog.</source><year>2018</year><volume>14</volume><fpage>e1007144</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1007144</pub-id><pub-id pub-id-type="pmid">29906292</pub-id><pub-id pub-id-type="pmcid">PMC6021110</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scriven</surname><given-names>JE</given-names></name><etal/></person-group><article-title>The CSF immune response in HIV-1-associated cryptococcal meningitis: macrophage activation, correlates of disease severity, and effect of antiretroviral therapy</article-title><source>J. Acquir. Immune Defic. Syndr.</source><year>2017</year><volume>75</volume><fpage>299</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000001382</pub-id><pub-id pub-id-type="pmid">28346317</pub-id><pub-id pub-id-type="pmcid">PMC5469563</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarvis</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><fpage>e1004754</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1004754</pub-id><pub-id pub-id-type="pmid">25853653</pub-id><pub-id pub-id-type="pmcid">PMC4390200</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarvis</surname><given-names>JN</given-names></name><etal/></person-group><article-title>The phenotype of the <italic toggle="yes">Cryptococcus</italic>-specific CD4<sup>+</sup> memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis</article-title><source>J. Infect. Dis.</source><year>2013</year><volume>207</volume><fpage>1817</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit099</pub-id><pub-id pub-id-type="pmid">23493728</pub-id><pub-id pub-id-type="pmcid">PMC3654748</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarvis</surname><given-names>JN</given-names></name><etal/></person-group><article-title>Adjunctive interferon-&#947; immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial</article-title><source>AIDS</source><year>2012</year><volume>26</volume><fpage>1105</fpage><lpage>1113</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e3283536a93</pub-id><pub-id pub-id-type="pmid">22421244</pub-id><pub-id pub-id-type="pmcid">PMC3640254</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anjum</surname><given-names>S</given-names></name><etal/></person-group><article-title>Outcomes in previously healthy cryptococcal meningoencephalitis patients treated with pulse taper corticosteroids for post-infectious inflammatory syndrome</article-title><source>Clin. Infect. Dis.</source><year>2021</year><volume>73</volume><fpage>e2789</fpage><lpage>e2798</lpage><pub-id pub-id-type="doi">10.1093/cid/ciaa1901</pub-id><pub-id pub-id-type="pmid">33383587</pub-id><pub-id pub-id-type="pmcid">PMC8563180</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panackal</surname><given-names>AA</given-names></name><etal/></person-group><article-title>Paradoxical immune responses in non-HIV cryptococcal meningitis</article-title><source>PLoS Pathog.</source><year>2015</year><volume>11</volume><fpage>e1004884</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1004884</pub-id><pub-id pub-id-type="pmid">26020932</pub-id><pub-id pub-id-type="pmcid">PMC4447450</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Chemokine receptor CXCR3 is required for lethal brain pathology but not pathogen clearance during cryptococcal meningoencephalitis</article-title><source>Sci. Adv.</source><year>2020</year><volume>6</volume><fpage>eaba2502</fpage><pub-id pub-id-type="doi">10.1126/sciadv.aba2502</pub-id><pub-id pub-id-type="pmid">32596454</pub-id><pub-id pub-id-type="pmcid">PMC7299622</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonelli</surname><given-names>LR</given-names></name><etal/></person-group><article-title>Elevated frequencies of highly activated CD4<sup>+</sup> T cells in HIV<sup>+</sup> patients developing immune reconstitution inflammatory syndrome</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>3818</fpage><lpage>3827</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-05-285080</pub-id><pub-id pub-id-type="pmid">20660788</pub-id><pub-id pub-id-type="pmcid">PMC2981537</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khaw</surname><given-names>YM</given-names></name><etal/></person-group><article-title>Th1-dependent cryptococcus-associated immune reconstitution inflammatory syndrome model with brain damage</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>529219</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.529219</pub-id><pub-id pub-id-type="pmid">33133067</pub-id><pub-id pub-id-type="pmcid">PMC7550401</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hsu</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Immunogenetics associated with severe coccidioidomycosis</article-title><source>JCI Insight</source><year>2022</year><pub-id pub-id-type="doi">10.1172/jci.insight.159491</pub-id><pub-id pub-id-type="pmcid">PMC9746810</pub-id><pub-id pub-id-type="pmid">36166305</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wuthrich</surname><given-names>M</given-names></name><name name-style="western"><surname>Deepe</surname><given-names>GS</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Klein</surname><given-names>B</given-names></name></person-group><article-title>Adaptive immunity to fungi</article-title><source>Annu. Rev. Immunol.</source><year>2012</year><volume>30</volume><fpage>115</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-020711-074958</pub-id><pub-id pub-id-type="pmid">22224780</pub-id><pub-id pub-id-type="pmcid">PMC3584681</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subramanian Vignesh</surname><given-names>K</given-names></name><name name-style="western"><surname>Landero Figueroa</surname><given-names>JA</given-names></name><name name-style="western"><surname>Porollo</surname><given-names>A</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>JA</given-names></name><name name-style="western"><surname>Deepe</surname><given-names>GS</given-names><suffix>Jr.</suffix></name></person-group><article-title>Granulocyte macrophage-colony stimulating factor induced Zn sequestration enhances macrophage superoxide and limits intracellular pathogen survival</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>697</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.09.006</pub-id><pub-id pub-id-type="pmid">24138881</pub-id><pub-id pub-id-type="pmcid">PMC3841917</pub-id></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wuthrich</surname><given-names>M</given-names></name><name name-style="western"><surname>Ersland</surname><given-names>K</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>T</given-names></name><name name-style="western"><surname>Galles</surname><given-names>K</given-names></name><name name-style="western"><surname>Klein</surname><given-names>BS</given-names></name></person-group><article-title>Fungi subvert vaccine T cell priming at the respiratory mucosa by preventing chemokine-induced influx of inflammatory monocytes</article-title><source>Immunity</source><year>2012</year><volume>36</volume><fpage>680</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.02.015</pub-id><pub-id pub-id-type="pmid">22483803</pub-id><pub-id pub-id-type="pmcid">PMC3334432</pub-id></element-citation></ref><ref id="CR147"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>M</given-names></name><etal/></person-group><article-title>Disseminated coccidioidomycosis treated with interferon-gamma and dupilumab</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>382</volume><fpage>2337</fpage><lpage>2343</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2000024</pub-id><pub-id pub-id-type="pmid">32521134</pub-id><pub-id pub-id-type="pmcid">PMC7333509</pub-id></element-citation></ref><ref id="CR148"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vargas</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants</article-title><source>Clin. Infect. Dis.</source><year>2001</year><volume>32</volume><fpage>855</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1086/319340</pub-id><pub-id pub-id-type="pmid">11247708</pub-id></element-citation></ref><ref id="CR149"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoving</surname><given-names>JC</given-names></name><name name-style="western"><surname>Kolls</surname><given-names>JK</given-names></name></person-group><article-title>New advances in understanding the host immune response to Pneumocystis</article-title><source>Curr. Opin. Microbiol.</source><year>2017</year><volume>40</volume><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2017.10.019</pub-id><pub-id pub-id-type="pmid">29136537</pub-id><pub-id pub-id-type="pmcid">PMC5733705</pub-id></element-citation></ref><ref id="CR150"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsegeiny</surname><given-names>W</given-names></name><etal/></person-group><article-title>Murine models of Pneumocystis infection recapitulate human primary immune disorders</article-title><source>JCI Insight</source><year>2018</year><volume>3</volume><fpage>e91894</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.91894</pub-id><pub-id pub-id-type="pmid">29925696</pub-id><pub-id pub-id-type="pmcid">PMC6124425</pub-id></element-citation></ref><ref id="CR151"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Opata</surname><given-names>MM</given-names></name><etal/></person-group><article-title>B lymphocytes are required during the early priming of CD4<sup>+</sup> T cells for clearance of pneumocystis infection in mice</article-title><source>J. Immunol.</source><year>2015</year><volume>195</volume><fpage>611</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1500112</pub-id><pub-id pub-id-type="pmid">26041535</pub-id><pub-id pub-id-type="pmcid">PMC4491042</pub-id></element-citation></ref><ref id="CR152"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rapaka</surname><given-names>RR</given-names></name><etal/></person-group><article-title>Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina</article-title><source>J. Exp. Med.</source><year>2010</year><volume>207</volume><fpage>2907</fpage><lpage>2919</lpage><pub-id pub-id-type="doi">10.1084/jem.20100034</pub-id><pub-id pub-id-type="pmid">21149550</pub-id><pub-id pub-id-type="pmcid">PMC3005228</pub-id></element-citation></ref><ref id="CR153"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steele</surname><given-names>C</given-names></name><etal/></person-group><article-title>Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the dectin-1 beta-glucan receptor</article-title><source>J. Exp. Med.</source><year>2003</year><volume>198</volume><fpage>1677</fpage><lpage>1688</lpage><pub-id pub-id-type="doi">10.1084/jem.20030932</pub-id><pub-id pub-id-type="pmid">14657220</pub-id><pub-id pub-id-type="pmcid">PMC2194130</pub-id></element-citation></ref><ref id="CR154"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eddens</surname><given-names>T</given-names></name><etal/></person-group><article-title>Eosinophils contribute to early clearance of Pneumocystis murina infection</article-title><source>J. Immunol.</source><year>2015</year><volume>195</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1403162</pub-id><pub-id pub-id-type="pmid">25994969</pub-id><pub-id pub-id-type="pmcid">PMC4475669</pub-id></element-citation></ref><ref id="CR155"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Limper</surname><given-names>AH</given-names></name><name name-style="western"><surname>Hoyte</surname><given-names>JS</given-names></name><name name-style="western"><surname>Standing</surname><given-names>JE</given-names></name></person-group><article-title>The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung</article-title><source>J. Clin. Invest.</source><year>1997</year><volume>99</volume><fpage>2110</fpage><lpage>2117</lpage><pub-id pub-id-type="doi">10.1172/JCI119384</pub-id><pub-id pub-id-type="pmid">9151783</pub-id><pub-id pub-id-type="pmcid">PMC508041</pub-id></element-citation></ref><ref id="CR156"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>XV</given-names></name><name name-style="western"><surname>Leonardi</surname><given-names>I</given-names></name><name name-style="western"><surname>Iliev</surname><given-names>ID</given-names></name></person-group><article-title>Gut mycobiota in immunity and inflammatory disease</article-title><source>Immunity</source><year>2019</year><volume>50</volume><fpage>1365</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.05.023</pub-id><pub-id pub-id-type="pmid">31216461</pub-id><pub-id pub-id-type="pmcid">PMC6585451</pub-id></element-citation></ref><ref id="CR157"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Underhill</surname><given-names>DM</given-names></name><name name-style="western"><surname>Braun</surname><given-names>J</given-names></name></person-group><article-title>Fungal microbiome in inflammatory bowel disease: a critical assessment</article-title><source>J. Clin. Invest.</source><year>2022</year><volume>132</volume><fpage>e155786</fpage><pub-id pub-id-type="doi">10.1172/JCI155786</pub-id><pub-id pub-id-type="pmid">35229726</pub-id><pub-id pub-id-type="pmcid">PMC8884899</pub-id></element-citation></ref><ref id="CR158"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Tilburg Bernardes</surname><given-names>E</given-names></name><etal/></person-group><article-title>Intestinal fungi are causally implicated in microbiome assembly and immune development in mice</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>2577</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-16431-1</pub-id><pub-id pub-id-type="pmid">32444671</pub-id><pub-id pub-id-type="pmcid">PMC7244730</pub-id></element-citation></ref><ref id="CR159"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>C</given-names></name><etal/></person-group><article-title>Multi-kingdom ecological drivers of microbiota assembly in preterm infants</article-title><source>Nature</source><year>2021</year><volume>591</volume><fpage>633</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03241-8</pub-id><pub-id pub-id-type="pmid">33627867</pub-id><pub-id pub-id-type="pmcid">PMC7990694</pub-id></element-citation></ref><ref id="CR160"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santus</surname><given-names>W</given-names></name><name name-style="western"><surname>Devlin</surname><given-names>JR</given-names></name><name name-style="western"><surname>Behnsen</surname><given-names>J</given-names></name></person-group><article-title>Crossing kingdoms: how the mycobiota and fungal-bacterial interactions impact host health and disease</article-title><source>Infect. Immun.</source><year>2021</year><volume>89</volume><fpage>e00648-20</fpage><pub-id pub-id-type="doi">10.1128/IAI.00648-20</pub-id><pub-id pub-id-type="pmid">33526565</pub-id><pub-id pub-id-type="pmcid">PMC8090948</pub-id></element-citation></ref><ref id="CR161"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boutin</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Bacterial-fungal interactions in the neonatal gut influence asthma outcomes later in life</article-title><source>Elife</source><year>2021</year><volume>10</volume><fpage>e67740</fpage><pub-id pub-id-type="doi">10.7554/eLife.67740</pub-id><pub-id pub-id-type="pmid">33876729</pub-id><pub-id pub-id-type="pmcid">PMC8075585</pub-id></element-citation></ref><ref id="CR162"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacher</surname><given-names>P</given-names></name><etal/></person-group><article-title>Human anti-fungal Th17 immunity and pathology rely on cross-reactivity against Candida albicans</article-title><source>Cell</source><year>2019</year><volume>176</volume><fpage>1340</fpage><lpage>1355 e1315</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.01.041</pub-id><pub-id pub-id-type="pmid">30799037</pub-id></element-citation></ref><ref id="CR163"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Findley</surname><given-names>K</given-names></name><etal/></person-group><article-title>Topographic diversity of fungal and bacterial communities in human skin</article-title><source>Nature</source><year>2013</year><volume>498</volume><fpage>367</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1038/nature12171</pub-id><pub-id pub-id-type="pmid">23698366</pub-id><pub-id pub-id-type="pmcid">PMC3711185</pub-id></element-citation></ref><ref id="CR164"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sparber</surname><given-names>F</given-names></name><etal/></person-group><article-title>The skin commensal yeast malassezia triggers a type 17 response that coordinates anti-fungal immunity and exacerbates skin inflammation</article-title><source>Cell Host Microbe</source><year>2019</year><volume>25</volume><fpage>389</fpage><lpage>403 e386</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.02.002</pub-id><pub-id pub-id-type="pmid">30870621</pub-id></element-citation></ref><ref id="CR165"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hurabielle</surname><given-names>C</given-names></name><etal/></person-group><article-title>Immunity to commensal skin fungi promotes psoriasiform skin inflammation</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2020</year><volume>117</volume><fpage>16465</fpage><lpage>16474</lpage><pub-id pub-id-type="doi">10.1073/pnas.2003022117</pub-id><pub-id pub-id-type="pmid">32601220</pub-id><pub-id pub-id-type="pmcid">PMC7368261</pub-id></element-citation></ref><ref id="CR166"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ost</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Adaptive immunity induces mutualism between commensal eukaryotes</article-title><source>Nature</source><year>2021</year><volume>596</volume><fpage>114</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03722-w</pub-id><pub-id pub-id-type="pmid">34262174</pub-id><pub-id pub-id-type="pmcid">PMC8904204</pub-id></element-citation></ref><ref id="CR167"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doron</surname><given-names>I</given-names></name><etal/></person-group><article-title>Mycobiota-induced IgA antibodies regulate fungal commensalism in the gut and are dysregulated in Crohn&#8217;s disease</article-title><source>Nat. Microbiol.</source><year>2021</year><volume>6</volume><fpage>1493</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1038/s41564-021-00983-z</pub-id><pub-id pub-id-type="pmid">34811531</pub-id><pub-id pub-id-type="pmcid">PMC8622360</pub-id></element-citation></ref><ref id="CR168"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doron</surname><given-names>I</given-names></name><etal/></person-group><article-title>Human gut mycobiota tune immunity via CARD9-dependent induction of anti-fungal IgG antibodies</article-title><source>Cell</source><year>2021</year><volume>184</volume><fpage>1017</fpage><lpage>1031 e1014</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.01.016</pub-id><pub-id pub-id-type="pmid">33548172</pub-id><pub-id pub-id-type="pmcid">PMC7936855</pub-id></element-citation></ref><ref id="CR169"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>B</given-names></name><etal/></person-group><article-title>High-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis</article-title><source>Nat. Med.</source><year>2020</year><volume>26</volume><fpage>59</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0709-7</pub-id><pub-id pub-id-type="pmid">31907459</pub-id><pub-id pub-id-type="pmcid">PMC7005909</pub-id></element-citation></ref><ref id="CR170"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rolling</surname><given-names>T</given-names></name><etal/></person-group><article-title>Haematopoietic cell transplantation outcomes are linked to intestinal mycobiota dynamics and an expansion of Candida parapsilosis complex species</article-title><source>Nat. Microbiol.</source><year>2021</year><volume>6</volume><fpage>1505</fpage><lpage>1515</lpage><pub-id pub-id-type="doi">10.1038/s41564-021-00989-7</pub-id><pub-id pub-id-type="pmid">34764444</pub-id><pub-id pub-id-type="pmcid">PMC8939874</pub-id></element-citation></ref><ref id="CR171"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malard</surname><given-names>F</given-names></name><etal/></person-group><article-title>Impact of gut fungal and bacterial communities on the outcome of allogeneic hematopoietic cell transplantation</article-title><source>Mucosal Immunol.</source><year>2021</year><volume>14</volume><fpage>1127</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1038/s41385-021-00429-z</pub-id><pub-id pub-id-type="pmid">34282272</pub-id></element-citation></ref><ref id="CR172"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sokol</surname><given-names>H</given-names></name><etal/></person-group><article-title>Fungal microbiota dysbiosis in IBD</article-title><source>Gut</source><year>2017</year><volume>66</volume><fpage>1039</fpage><lpage>1048</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2015-310746</pub-id><pub-id pub-id-type="pmid">26843508</pub-id><pub-id pub-id-type="pmcid">PMC5532459</pub-id></element-citation></ref><ref id="CR173"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonardi</surname><given-names>I</given-names></name><etal/></person-group><article-title>CX3CR1<sup>+</sup> mononuclear phagocytes control immunity to intestinal fungi</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>232</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1126/science.aao1503</pub-id><pub-id pub-id-type="pmid">29326275</pub-id><pub-id pub-id-type="pmcid">PMC5805464</pub-id></element-citation></ref><ref id="CR174"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Limon</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Malassezia is associated with Crohn&#8217;s disease and exacerbates colitis in mouse models</article-title><source>Cell Host Microbe</source><year>2019</year><volume>25</volume><fpage>377</fpage><lpage>388 e376</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.01.007</pub-id><pub-id pub-id-type="pmid">30850233</pub-id><pub-id pub-id-type="pmcid">PMC6417942</pub-id></element-citation></ref><ref id="CR175"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>U</given-names></name><etal/></person-group><article-title>Debaryomyces is enriched in Crohn&#8217;s disease intestinal tissue and impairs healing in mice</article-title><source>Science</source><year>2021</year><volume>371</volume><fpage>1154</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1126/science.abd0919</pub-id><pub-id pub-id-type="pmid">33707263</pub-id><pub-id pub-id-type="pmcid">PMC10114606</pub-id></element-citation></ref><ref id="CR176"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iliev</surname><given-names>ID</given-names></name><etal/></person-group><article-title>Interactions between commensal fungi and the C-type lectin receptor dectin-1 influence colitis</article-title><source>Science</source><year>2012</year><volume>336</volume><fpage>1314</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1126/science.1221789</pub-id><pub-id pub-id-type="pmid">22674328</pub-id><pub-id pub-id-type="pmcid">PMC3432565</pub-id></element-citation></ref><ref id="CR177"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGovern</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Genome-wide association identifies multiple ulcerative colitis susceptibility loci</article-title><source>Nat. Genet.</source><year>2010</year><volume>42</volume><fpage>332</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/ng.549</pub-id><pub-id pub-id-type="pmid">20228799</pub-id><pub-id pub-id-type="pmcid">PMC3087600</pub-id></element-citation></ref><ref id="CR178"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leonardi</surname><given-names>I</given-names></name><etal/></person-group><article-title>Fungal trans-kingdom dynamics linked to responsiveness to fecal microbiota transplantation (FMT) therapy in ulcerative colitis</article-title><source>Cell Host Microbe</source><year>2020</year><volume>27</volume><fpage>823</fpage><lpage>829 e823</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.03.006</pub-id><pub-id pub-id-type="pmid">32298656</pub-id><pub-id pub-id-type="pmcid">PMC8647676</pub-id></element-citation></ref><ref id="CR179"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>XV</given-names></name><etal/></person-group><article-title>Immune regulation by fungal strain diversity in inflammatory bowel disease</article-title><source>Nature</source><year>2022</year><volume>603</volume><fpage>672</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04502-w</pub-id><pub-id pub-id-type="pmid">35296857</pub-id><pub-id pub-id-type="pmcid">PMC9166917</pub-id></element-citation></ref><ref id="CR180"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aykut</surname><given-names>B</given-names></name><etal/></person-group><article-title>The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL</article-title><source>Nature</source><year>2019</year><volume>574</volume><fpage>264</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1608-2</pub-id><pub-id pub-id-type="pmid">31578522</pub-id><pub-id pub-id-type="pmcid">PMC6858566</pub-id></element-citation></ref><ref id="CR181"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiao</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Commensal bacteria and fungi differentially regulate tumor responses to radiation therapy</article-title><source>Cancer Cell</source><year>2021</year><volume>39</volume><fpage>1202</fpage><lpage>1213 e1206</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2021.07.002</pub-id><pub-id pub-id-type="pmid">34329585</pub-id><pub-id pub-id-type="pmcid">PMC8830498</pub-id></element-citation></ref><ref id="CR182"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dohlman</surname><given-names>AB</given-names></name><etal/></person-group><article-title>A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>3807</fpage><lpage>3822 e3812</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.09.015</pub-id><pub-id pub-id-type="pmid">36179671</pub-id><pub-id pub-id-type="pmcid">PMC9564002</pub-id></element-citation></ref><ref id="CR183"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narunsky-Haziza</surname><given-names>L</given-names></name><etal/></person-group><article-title>Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>3789</fpage><lpage>3806 e3717</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.09.005</pub-id><pub-id pub-id-type="pmid">36179670</pub-id><pub-id pub-id-type="pmcid">PMC9567272</pub-id></element-citation></ref><ref id="CR184"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lasbury</surname><given-names>ME</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Durant</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CH</given-names></name></person-group><article-title>Effect of transcription factor GATA-2 on phagocytic activity of alveolar macrophages from Pneumocystis carinii-infected hosts</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>4943</fpage><lpage>4952</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.9.4943-4952.2003</pub-id><pub-id pub-id-type="pmid">12933836</pub-id><pub-id pub-id-type="pmcid">PMC187340</pub-id></element-citation></ref><ref id="CR185"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Proctor</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Integrated genomic, epidemiologic investigation of Candida auris skin colonization in a skilled nursing facility</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>1401</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01383-w</pub-id><pub-id pub-id-type="pmid">34155414</pub-id><pub-id pub-id-type="pmcid">PMC9396956</pub-id></element-citation></ref><ref id="CR186"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathur</surname><given-names>P</given-names></name><etal/></person-group><article-title>Five-year profile of candidaemia at an Indian trauma centre: high rates of Candida auris blood stream infections</article-title><source>Mycoses</source><year>2018</year><volume>61</volume><fpage>674</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1111/myc.12790</pub-id><pub-id pub-id-type="pmid">29738604</pub-id></element-citation></ref><ref id="CR187"><label>187.</label><mixed-citation publication-type="other">CDC. Antibiotic resistance threats in the United States, 2019. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf">https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf</ext-link> (2019).</mixed-citation></ref><ref id="CR188"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eix</surname><given-names>EF</given-names></name><etal/></person-group><article-title>Ex vivo human and porcine skin effectively model Candida auris colonization, differentiating robust and poor fungal colonizers</article-title><source>J. Infect. Dis.</source><year>2022</year><volume>225</volume><fpage>1791</fpage><lpage>1795</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiac094</pub-id><pub-id pub-id-type="pmid">35267041</pub-id><pub-id pub-id-type="pmcid">PMC9113498</pub-id></element-citation></ref><ref id="CR189"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Murine model of colonization with fungal pathogen Candida auris to explore skin tropism, host risk factors and therapeutic strategies</article-title><source>Cell Host Microbe</source><year>2020</year><volume>29</volume><fpage>210</fpage><lpage>221.e6</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.12.002</pub-id><pub-id pub-id-type="pmid">33385336</pub-id><pub-id pub-id-type="pmcid">PMC7878403</pub-id></element-citation></ref><ref id="CR190"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruno</surname><given-names>M</given-names></name><etal/></person-group><article-title>Transcriptional and functional insights into the host immune response against the emerging fungal pathogen Candida auris</article-title><source>Nat. Microbiol.</source><year>2020</year><volume>5</volume><fpage>1516</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1038/s41564-020-0780-3</pub-id><pub-id pub-id-type="pmid">32839538</pub-id><pub-id pub-id-type="pmcid">PMC9204844</pub-id></element-citation></ref><ref id="CR191"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Davis</surname><given-names>JM</given-names></name><name name-style="western"><surname>Huttenlocher</surname><given-names>A</given-names></name><name name-style="western"><surname>Kernien</surname><given-names>JF</given-names></name><name name-style="western"><surname>Nett</surname><given-names>JE</given-names></name></person-group><article-title>Emerging fungal pathogen <italic toggle="yes">Candida auris</italic> evades neutrophil attack</article-title><source>mBio</source><year>2018</year><volume>9</volume><fpage>e01403-18</fpage><pub-id pub-id-type="doi">10.1128/mBio.01403-18</pub-id><pub-id pub-id-type="pmid">30131360</pub-id><pub-id pub-id-type="pmcid">PMC6106086</pub-id></element-citation></ref><ref id="CR192"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>LVN</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R</given-names></name><name name-style="western"><surname>Specht</surname><given-names>CA</given-names></name><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name></person-group><article-title>Vaccines for human fungal diseases: close but still a long way to go</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>33</fpage><pub-id pub-id-type="doi">10.1038/s41541-021-00294-8</pub-id><pub-id pub-id-type="pmid">33658522</pub-id><pub-id pub-id-type="pmcid">PMC7930017</pub-id></element-citation></ref><ref id="CR193"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rivera</surname><given-names>A</given-names></name><name name-style="western"><surname>Lodge</surname><given-names>J</given-names></name><name name-style="western"><surname>Xue</surname><given-names>C</given-names></name></person-group><article-title>Harnessing the immune response to fungal pathogens for vaccine development</article-title><source>Annu. Rev. Microbiol.</source><year>2022</year><volume>76</volume><fpage>703</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-041020-111511</pub-id><pub-id pub-id-type="pmid">35759871</pub-id><pub-id pub-id-type="pmcid">PMC11926770</pub-id></element-citation></ref><ref id="CR194"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappagianis</surname><given-names>D</given-names></name><collab>Valley Fever Vaccine Study Group.</collab></person-group><article-title>Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans</article-title><source>Am. Rev. Respir. Dis.</source><year>1993</year><volume>148</volume><fpage>656</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1164/ajrccm/148.3.656</pub-id><pub-id pub-id-type="pmid">8368636</pub-id></element-citation></ref><ref id="CR195"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Bernardis</surname><given-names>F</given-names></name><name name-style="western"><surname>Graziani</surname><given-names>S</given-names></name><name name-style="western"><surname>Tirelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Antonopoulou</surname><given-names>S</given-names></name></person-group><article-title>Candida vaginitis: virulence, host response and vaccine prospects</article-title><source>Med. Mycol.</source><year>2018</year><volume>56</volume><fpage>26</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1093/mmy/myx139</pub-id><pub-id pub-id-type="pmid">29538739</pub-id></element-citation></ref><ref id="CR196"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>L</given-names></name><etal/></person-group><article-title>Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice</article-title><source>PLoS Pathog.</source><year>2009</year><volume>5</volume><fpage>e1000703</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1000703</pub-id><pub-id pub-id-type="pmid">20041174</pub-id><pub-id pub-id-type="pmcid">PMC2792038</pub-id></element-citation></ref><ref id="CR197"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><etal/></person-group><article-title>The NDV-3A vaccine protects mice from multidrug resistant Candida auris infection</article-title><source>PLoS Pathog.</source><year>2019</year><volume>15</volume><fpage>e1007460</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1007460</pub-id><pub-id pub-id-type="pmid">31381597</pub-id><pub-id pub-id-type="pmcid">PMC6695204</pub-id></element-citation></ref><ref id="CR198"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spellberg</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis</article-title><source>J. Infect. Dis.</source><year>2006</year><volume>194</volume><fpage>256</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1086/504691</pub-id><pub-id pub-id-type="pmid">16779733</pub-id></element-citation></ref><ref id="CR199"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>CS</given-names></name><etal/></person-group><article-title>NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>7594</fpage><lpage>7600</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.038</pub-id><pub-id pub-id-type="pmid">23099329</pub-id><pub-id pub-id-type="pmcid">PMC3513491</pub-id></element-citation></ref><ref id="CR200"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wuthrich</surname><given-names>M</given-names></name><etal/></person-group><article-title>Calnexin induces expansion of antigen-specific CD4<sup>+</sup> T cells that confer immunity to fungal ascomycetes via conserved epitopes</article-title><source>Cell Host Microbe</source><year>2015</year><volume>17</volume><fpage>452</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2015.02.009</pub-id><pub-id pub-id-type="pmid">25800545</pub-id><pub-id pub-id-type="pmcid">PMC4484745</pub-id></element-citation></ref><ref id="CR201"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Emerging fungal threats to animal, plant and ecosystem health</article-title><source>Nature</source><year>2012</year><volume>484</volume><fpage>186</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/nature10947</pub-id><pub-id pub-id-type="pmid">22498624</pub-id><pub-id pub-id-type="pmcid">PMC3821985</pub-id></element-citation></ref><ref id="CR202"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nilsson</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Mycobiome diversity: high-throughput sequencing and identification of fungi</article-title><source>Nat. Rev. Microbiol.</source><year>2019</year><volume>17</volume><fpage>95</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0116-y</pub-id><pub-id pub-id-type="pmid">30442909</pub-id></element-citation></ref><ref id="CR203"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nash</surname><given-names>AK</given-names></name><etal/></person-group><article-title>The gut mycobiome of the human microbiome project healthy cohort</article-title><source>Microbiome</source><year>2017</year><volume>5</volume><fpage>153</fpage><pub-id pub-id-type="doi">10.1186/s40168-017-0373-4</pub-id><pub-id pub-id-type="pmid">29178920</pub-id><pub-id pub-id-type="pmcid">PMC5702186</pub-id></element-citation></ref><ref id="CR204"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Auchtung</surname><given-names>TA</given-names></name><etal/></person-group><article-title>Investigating colonization of the healthy adult gastrointestinal tract by fungi</article-title><source>mSphere</source><year>2018</year><volume>3</volume><fpage>e00092-18</fpage><pub-id pub-id-type="doi">10.1128/mSphere.00092-18</pub-id><pub-id pub-id-type="pmid">29600282</pub-id><pub-id pub-id-type="pmcid">PMC5874442</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>